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Summary   
 
The fms-like tyrosine kinase 3 receptor (flt3) and ligand (flt3L) are important 
regulators of early haematopoiesis (1). Uncontrolled activity of flt3 is associated with 
acute myeloid leukaemia, making flt3 a major target of receptor tyrosine kinase 
inhibitors (TKIs) (2). TKIs are currently used in a variety of malignancies and 
patients have experienced cardiotoxicity under some of them. We recently 
demonstrated that exogenous activation of flt3 through intramyocardial injection of 
flt3L is cardioprotective and improves post-myocardial infarction remodeling and 
function in mice (3).  
Based on this background, we wanted to assess how endogenous disruption of flt3-
signaling affects the healthy and the injured heart. We also hypothesized that lack of 
flt3L has an impact on the adult cardiac progenitor cell pool, and, hence, on their 
contribution to cardiac homeostasis. 
We isolated cardiac progenitor cells (CPCs) according to the side population (SP) 
phenotype (SP-CPCs) from 12 week-old wt and flt3L-/- mice (4) and we further 
expanded the SP-CPC fraction positive for Sca1 and negative for CD31 in culture (5). 
Our in vivo findings showed a reduced number of SP-CPCs in flt3L-/- hearts, 
suggesting an untimely activation of a proportion of this physiologically quiescent 
population. In line with this finding, transcriptional comparison revealed a reduced 
CD31- progenitor cell signature in flt3L-/- SP-CPCs, with downregulation of 
transcripts involved in cell cycle arrest and stemness. Expanded SP-CPCs do express 
functional flt3 receptor and secrete flt3L allowing for an autocrine and/or paracrine 
activation of the receptor. SP-CPCs maintained the capacity to differentiate into 
different cardiac lineages when expanded under progenitor potential-preserving 
culturing conditions. However, in this context, flt3L-/- SP-CPCs showed enhanced 
proliferation capacity associated with reduced differentiation potential towards all 
three major cardiac lineages, i.e., cardiomyocytes, smooth muscle and endothelial 
cells. 
Echocardiography showed that disruption of flt3-signaling leads to significant systolic 
dysfunction and subtle structural alterations of the heart. Specifically, flt3L-/- hearts 
are smaller and exhibit reduced microvascularization within the ventricular wall. 
Together, these findings support that flt3-signaling is important for the maintenance 
of a functional CPC pool and cardiac homeostasis of the healthy heart. We further 
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investigated the implications of the lack of a functional flt3 system in a model of 
myocardial infarction. Given the importance of flt3 in cardiomyocyte survival (3) and 
myocardial microvascularization, we hypothesized that flt3-disruption may aggravate 
post-infarct myocardial damage and dysfunction. Contrary to this hypothesis, 
however, flt3L ablation mitigated the functional decline during the acute and post-
acute phase after myocardial infarction. This protective effect may involve potential 
immunomodulatory properties related to flt3-signaling as supported by our most 
recent RNA sequencing data. 
  
In summary, this thesis work shows that in a context of a potential prospective use of 
CPCs for cardiac cell therapy, careful adjustments of culturing conditions are pivotal 
to preserve the CPC potential, and thus the capability for multi-lineage commitment 
and differentiation, during ex vivo expansion.  
Furthermore, this work uncovers a so-far unrecognized role of flt3 signaling in the 
regulation of adult CPC homeostasis and function. In particular we showed that flt3 
contributes to the maintenance of a pool of quiescent, functional cardiac progenitor 
cells in vivo and their balanced proliferation and differentiation in vitro. 
Finally, our most recent data suggest that the systemic inhibition of flt3 may be 
protective during the early phase post-myocardial infarction. In view of the increasing 
use of TK targeting cancer therapies, improved understanding of the roles of such TK 
in cardiac health and disease is important in order to anticipate potential cardiac side 
effects. This work uncovers so far unknown functions of flt3 signaling in the healthy 
and injured heart that raise both awareness of potential cardiac toxicity, but also of a 
possible therapeutic effect of the systemic inhibition of flt3 in the post-acute phase 
after myocardial infarction. 	
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Introduction 
 
Chapter 1. Role of fms-like tyrosine kinase 3 receptor in health and disease  
 
Cancer kinome and its cardiotoxicity 
The human kinome is an ensemble defining above 500 kinases in the human genome.  
A clinical study screened 518 protein kinase genes for somatic mutations in varying 
types of human cancer. Excluding gene “passenger” mutations (random neutral 
mutation, which it is believed to have no role in cancer), they identified 
approximately 120 genes as plausible cause for the observed tumours (6). These 
protein kinases that can carry mutations, which may act as cancer “drivers” (or 
contribute to tumour growth), are defined as cancer kinome and are recognised as an 
attractive target for therapy against cancer via the use of the so-called kinase 
inhibitors (KIs). 
KI therapy has shown high efficiency with regard to cancer treatment (7, 8). Despite 
their beneficial effects, KIs are responsible for a simultaneous inhibition of the same 
kinases in the whole organism, including the heart, where these kinases may be 
important for cardiac cell homeostasis, and hence leading to cardiotoxic effects. 
Cardiotoxicity is a term used to describe a broad range of adverse effects on heart 
function induced by therapeutic molecules. These adverse events may impact on 
hemodynamics, electrical activity, or interfere with myocytes and progenitor cell 
function, and facilitate the development of cardiomyopathies.  
We distinguish two general types of cardiotoxicity. “On target” cardiotoxicity is 
induced by the inhibition of kinases that are specifically targeted by a chosen KI. In 
contrast, “off-target” cardiotoxicity is the cardiotoxic effect due to inhibition of 
kinases, for which the drug was not designed for, since none of these small-molecule 
inhibitors seem to be truly selective (9).  
Although past studies of cardiotoxicity have mainly focused on anthracyclines and 
radiotherapy (10), the increasing use of targeted therapies, such as KIs in general or 
receptor tyrosine kinase inhibitors (TKIs) in particular, for a variety of solid and 
hematologic malignancies has increased the need to investigate their related 
cardiotoxic effects (11).  
Several KIs have been shown to evoke adverse cardiac events, some of them being 
transient and/or reversible. The susceptibility to KIs to experience cardiotoxicity may 
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vary from patient to patient, making it difficult to identify patients truly at risk.  
An improved understanding of the cardiac functions of specific kinases targeted by 
KIs and of the underlying cellular and molecular mechanisms may help anticipate 
potential cardiotoxicity and identify and improve the management of high risk 
patients (12, 13).  
 
Cardiovascular risk in cancer patients 
The leading non cancer-related cause of morbidity and mortality in long-term cancer 
survivors is cardiovascular disease. Improvements in childhood cancer therapy have 
led to a growing number of long-term cancer survivors, but compared to age-matched 
healthy control subjects, they experience a 7-fold higher incidence of cardiovascular 
abnormalities or diseases and an 8-fold higher cardiac-related mortality rate (14-17).  
Cardiotoxicity related to cancer treatment may manifest as acute, when it occurs 
within the first week of treatment, early onset or late onset. Acute cardiotoxicity is 
mainly characterized by transient electrophysiological abnormalities, rare fatal 
arrhythmia or left ventricular (LV) dysfunction and, if resolved, patients remain at 
high risk for late cardiotoxic effects (18). Early or late onset cardiotoxicity occurs 
within a year or more respectively, and is characterized by persistent damage, mostly 
leading to heart failure (HF) due to loss of functional cardiomyocytes (CMCs) and 
reduced LV contractility (19). However, the degree and progression of the disease 
remains unpredictable due to a widely various susceptibility to anthracyclines or KIs 
among individuals and depends on concomitant additional cardiovascular risk factors 
such as smoking, diabetes, obesity, aging, et cetera. This accentuates the need for a 
cardiovascular program, which offers preventive care during and after cancer 
treatment, together with sensitive screening strategies to detect early subclinical 
cardiac dysfunction.  
To date, no agreed-upon preventive strategies to avoid cardiotoxicity exist. However, 
the pre-emptive initiation of standard HF therapy, such as the administration of 
angiotensin converting enzyme inhibitors or beta-blockers, has shown to reduce early 
acute cardiotoxicity in high risk patients (20). Dexrazoxane, a cardioprotective agent, 
which decreases oxygen free radicals through intracellular iron chelation, can 
decrease tissue damage induced by anthracyclines (21). However, reports of an 
increased incidence in hematologic malignancies later in life of young patients treated 
with dexrazoxane has limited its routine clinical use (22).  
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Nowadays several sensitive screening strategies exist, although the precise roles and 
the frequency of monitoring cardiac function is not clear. To date, cardiac magnetic 
resonance imaging (MRI) and echocardiography approaches are used as reference 
standard to detect LV dysfunction, but they lack sufficient sensitivity and specificity 
to detect early cardiac injury. Screening guidelines also suggest monitoring of 
biomarkers such as brain natriuretic peptide (BNP) (23) or serum cardiac troponin I, 
which are indicative of HF and cardiac injury respectively, and have shown to be 
elevated under chemotherapy (24).  
 
Flt3 signaling in haematopoiesis  
In this study we focused on the fms-like tyrosine kinase 3 (flt3) system, also known as 
fetal liver kinase 2 (flk2). Flt3 receptor exerts a functional role in early 
haematopoiesis upon binding with its own ligand (flt3L) (to date the only one 
identified), controlling proliferation and differentiation of hematopoietic progenitor 
cells.  
Flt3 belongs to the type III family of receptor tyrosine kinases (RTKs). It is expressed 
as a monomeric transmembrane receptor. Upon flt3L binding, two flt3 receptor 
molecules assemble to form a homodimer. Flt3 dimerization results in the 
phosphorylation of the tyrosine kinase domain (TKD), which triggers the activation of 
signal transduction pathways through activation of cytoplasmic molecules such as 
phosphoinositol-3-kinase (PI3K), Ras GTPase, phospholipase C-γ, Shc, growth factor 
receptor bound protein (Grb2) and Src family tyrosine kinase (Fig.1). Phosphorylation 
of these proteins affects further downstream signalling including Akt, Erk, and Stat3 
and 5, which are involved in several cellular processes (25) (Fig.2).  
 
 
 
Fig.1: flt3 receptor system triggered by flt3L binding (https://www.slideshare.net) 
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                Fig.2: Intracellular pathways involved in flt3 signaling (http://www.qiagen.com) 
 
 
Numerous studies have demonstrated that flt3L, supplemented in vitro (in synergy 
with other cytokines such as interleukin (IL) 3, granulocyte colony-stimulating factor, 
granulocyte macrophage colony-stimulating factor, stem cell factor (SCF), and IL-6) 
or administered in vivo (as single agent), stimulates the expansion and mobilization of 
hematopoietic progenitor cells (26-29).  
Mice that are knock-out (KO) for flt3 receptor (flk2-/-) or its ligand (flt3L-/-) exhibit 
hematologic defects, which are more severe in mice lacking the flt3L. Flk2-/- mice do 
not have variations in monocyte, granulocyte, and erythrocyte levels but B lymphoid 
precursor are reduced. Also the ability of mutant flk2-/- stem cells to reconstitute 
haematopoiesis in irradiated hosts is 5-fold reduced compared to wild-type (wt) 
competitors (30).  Flt3L-/- mice exhibit reduced leucocyte cellularity in bone marrow 
(BM), peripheral blood and lymph nodes, along with reduced numbers in myeloid and 
lymphoid progenitors. In contrast, erythrocyte and platelet production is not affected. 
In addition, flt3L-/- mice have a marked deficiency in natural killer and dendritic cells 
(DCs) (31). Different studies approached the role of flt3L in DC. A study in a mouse 
model shows that transplanted common lymphoid and common myeloid progenitors 
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increase their DC progeny when a subsequent flt3L injection is performed (32). Also 
the DC progenitor compartment in the BM is responsive to flt3L as it increases 
progenitor cell numbers, although it does not alter their ability to produce mature DCs. 
In contrast, DC homeostasis in the spleen depends on flt3-mediated signals.  
Importantly, more recent work by the group of A. Rolink and colleagues suggests an 
instructive role of flt3L in the commitment of multipotent progenitor cells towards 
myeloid and lymphoid lineage (33) and a permissive role of flt3L on the B-cell 
progenitor compartment through enhancing proliferation and possibly survival of their 
non-committed precursors (34). These findings support previous notions that flt3L 
acts in a cell type specific manner and exerts very distinct effects during 
hematopoiesis that heavily depend on the stage and context.  
 
Flt3 signaling in acute myeloid leukaemia 
Different kind of mutations leading to constitutive activation of flt3 are associated (in 
the presence of at least another mutated gene) with the development of acute myeloid 
leukaemia (AML), making the flt3 receptor itself an attractive target for cancer 
therapy (35). These mutations include internal tandem duplications (ITD) or point 
mutations of the kinase domain (TKD), although enhanced expression levels of wt 
flt3 also contributes to leukaemia. ITDs can be found in 17-26% of AML cases. The 
ITD occurs near the juxta-membrane domain and may negatively affect the auto-
inhibition of the catalytic activity of the receptor (Fig.3A). Flt3-TKD mutations, such 
as single-amino acid substitutions, are also associated with constitutive activation of 
the flt3 receptor. Usually, they encompass a missense point mutation at the D835 
residue and point mutations, deletions and insertions in the codons surrounding D835 
(Fig.3B). They are found in approximately 7% of AML patients (36). Likely this 
mutation favours an open ATP-binding conformation of the activation loop hence 
making the receptor prone to accept ATP molecules and exert its catalytic activity. 
Although flt3-ITD blasts express similar levels of flt3 receptor compared to wt 
leukemic blasts, the flt3-ITD receptor is flt3L non-responsive. Ligand independent 
flt3-ITD blasts express increased levels of p-Stat1, p-Stat3 and p-Stat5 but not 
increased basal levels of p-Erk and p-Akt (37). 
It was recently shown that flt3-ITD knock-in mice develop myeloproliferative 
neoplasms. Concomitant with the uncontrolled expansion of multipotent progenitor 
cells, flt3-ITD perturbs hematopoietic stem cell quiescence causing a proportion of 
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physiologically quiescent stem cells, such as the side population (SP), to leave their 
state and enter the cell cycle (38). 
 
                           
 
Fig.3: A. flt3 receptor domains (35). B. Activation loop mutations in the Tyrosine Kinase Domain (36). 
   
Flt3–targeting tyrosine kinase inhibitors induce cardiotoxicity 
Nowadays several TKIs targeting the flt3 receptor exist and cardiotoxicity has been 
observed under some of them. According to the modality of binding, TKIs can be 
classified in 4 different types. Type I inhibitors (e.g. sunitinib) recognize the ATP 
pocket of the kinase. This kind of TKIs are easy to design, but they are associated 
with a lack of selectivity due to the highly conserved structure of the ATP pocket 
across this class of human kinases. Type II inhibitors (e.g. sorafenib) target the ATP 
pocket and an adjacent site to it, thereby enhancing selectivity. A third class (type III) 
of inhibitors (quizartinib) is not competitive for the ATP pocket. They exhibit the 
highest specificity for the receptor binding, but insufficient knowledge of this unique 
portion of the receptor structure poses a challenge for drug design. Type IV inhibitors 
are designed to make a covalent bond with the kinase active site of the receptor (39). 
The first generation TKI sunitinib is approved for metastatic renal-cell carcinoma and 
gastrointestinal stromal tumours. This drug shows a predominant inhibitory capacity 
for KIT, platelet derived growth factor receptor (PDGFR), vascular endothelial 
growth factor receptor-2 (VEGFR) and flt3 receptor. In a phase I/II trial on imatinib-
resistant, metastatic, gastrointestinal stromal tumours, eight out of 75 patients 
experienced a cardiovascular event, with congestive HF (CHF) in 6 of them. Ten out 
of 36 patients receiving the approved dose of 50mg per day experienced an absolute 
reduction of the LV ejection fraction (LVEF) of at least 10%. Mechanisms of 
sunitinib cardiotoxicity were assessed in murine and rat cardiomyocytes. Murine 
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myocytes showed mitochondrial swelling and degeneration of the cristae. Being 
contractile units, myocytes have a high demand for ATP. Disturbance of the 
mitochondrial activity hence impairs energy generation and perturbs the contractile 
function. Sunitinib also causes cardiomyocyte apoptosis in mice and in cultured rat 
cardiomyocytes, likely via the mitochondrial death pathway (40).  
The second-generation flt3 inhibitors, including sorafenib, quizartinib and crenolanib 
(CP-868596), are more potent and selective than the first-generation inhibitors.  
Sorafenib is a multi-kinase inhibitor active against VEGFR, PDGFR, RAF-1, KIT, 
and flt3. Several AML studies have been conducted to assess sorafenib efficacy in 
combination with standard therapy. Again the treatment showed a higher impact on 
flt3 mutated-patients (41, 42).  
A cardiac toxicity study (n=74) of sorafenib and sunitib in patients with metastatic 
renal cell carcinoma showed that 10% of patients experienced a cardiovascular event, 
which mostly consisted of changes in electrocardiography. However, elevation of 
troponin T or reduced LVEF (in three of them) were also observed (43). Following 
these clinical results, mechanisms of sorafenib toxicity have been evaluated in mice 
undergoing myocardial infarction (MI) after 1 week of treatment. Sorafenib 
significantly reduced the survival of mice in the two weeks following MI compared to 
vehicle treated mice. However, there were no differences regarding conventional 
functional parameters as LVEF and fractional shortening, but sorafenib-treated hearts 
were smaller and histological analysis showed an increased myocytes cross-sectional 
area suggesting loss of myocytes in vivo. Through BrdU incorporation strategy, they 
also showed that sorafenib reduced the number of myocytes and non-myocytes 
undergoing S-phase DNA replication in the infarct border zone. As for sunitinib, high 
dose of sorafenib induced myocyte necrotic death in vitro (44).  These findings 
confirm previous clinical observations that cardiotoxicity might manifest and/or be 
more pronounced in the setting of aggravating factors, such as concomitant MI in this 
study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 
Quizartinib (AC220) (Fig.4) is a novel non ATP-competitive compound developed to 
treat flt3-mutant AML. Quizartinib has a high flt3 binding affinity with a Kd 1.6nM 
(second only to Sunitib) and is the most potent cellular flt3-ITD inhibitor when tested 
in the human cell line MV4-11, which holds a homozygous flt3-ITD mutation. A 
screening through a 402 kinases binding assay, representing almost 80% of human 
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protein kinases revealed flt3 has the highest affinity for the drug. Although with a 10-
fold higher Kd, the assay showed also binding affinity for other class III RTKs such as 
KIT, PDGFRA, PDGFRB, RET, and CSF1R (45). This off-target inhibition of mutant 
PDGFR and KIT isoforms was confirmed by an additional study (46). Quizartinib led 
to in vitro inhibition of cellular proliferation of mutant flt3, KIT or PDGFRA 
leukaemia cell lines in a dose dependent manner.  The anti-proliferative effect was 
accompanied by a pro-apoptotic effect in cells harbouring activating-mutation on 
class III RTKs (45). 
Quizartinib efficacy was evaluated in vivo in a xenograft tumour model, in which 
leukemic human MV4-11 cells were implanted subcutaneously into mice to establish 
the disease. Quizartinib was administrated for 28 days at 10mg/kg/day (to avoid 
cytotoxic effects but still to approach an IC50 during the course of the treatment). 
Mice treated with quizartinib showed complete regression of the tumour with no 
regrowth during the 60-days post-treatment observation period. In a more 
physiologically relevant model, in which leukemic MV4-11 cells were injected into 
BM-ablated mice, quizartinib showed a prolonged dose-dependent survival, with 80% 
survival at 10mg/kg/day administration (45). 
A phase II study enrolled two cohorts of patients (n=333), including patients greater 
than 60 years old, who relapsed within <1 year or were refractory to first-line 
chemotherapy (cohort I), and patients greater than 18 yeas old refractory to second-
line, salvage chemotherapy or relapsed after hematopoietic stem cells transplantation 
(HSCT) (cohort II, n=137). The majority of the patients were flt3-ITD and were 
treated with quizartinib continuously for 28 days. In cohort I, composite complete 
response (which includes complete remission with or without platelet and/or 
hematologic recovery) was demonstrated in 54% of patients harbouring flt3-ITD 
mutation compared with 31% in the flt3-wt group. Flt3-ITD patients in cohort II again 
demonstrated a higher composite complete remission rate: 44% versus 34% in the 
flt3-wt subset. Of note, in flt3-ITD population, which relapsed after their first AML 
therapy, 37% of patients were successfully bridged to HSCT. Taken together, these 
preclinical and clinical studies demonstrated the high efficacy of quizartinib in the 
treatment of wt as well as flt3-ITD-driven leukemia. 
The side-effect profile of quizartinib showed primarily myelosuppression and QTc 
prolongation, which was transient and non-fatal (47). 
Several clinical trials assessing quizartinib in patients are currently active or recruiting. 
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These trials address both the efficacy of quizartinib as monotherapy or in combination 
with conventional treatment or hematopoietic stem cell transplantation (2). 
One of the major problems disclosed through early phases of clinical trial is the 
development of several resistance mechanisms against the flt3 inhibitor (36, 48). A 
primary resistance comprises of the low efficacy on mutations that differ from flt3-
ITD, such as flt3-TKD mutation (although they correlate less with development of 
AML), and the compensatory up-regulation of parallel or downstream pathways. In 
contrast, secondary resistance arises from acquisition of new resistance mutations. It 
has been shown that D835Y, D835V, D835F or F691L mutations were additionally 
acquired in flt3-ITD patients treated with quizartinib monotherapy (49). Currently, 
there are two main ways to overcome acquired resistance during early phases of drug 
delivery. One way is the combinatorial use of different TKIs, since flt3 receptor could 
develop a point mutation and consequently resistance to a TKI, but still preserves 
sensitivity to a new agent. The other way consists of the use of an alternative flt3 
inhibitor, which is selective and sensitive against both flt3-ITD and flt3-TKD 
mutations. At present, crenolanib is under clinical evaluation. In a phase II trial of 
patients with relapsed or refractory AML, crenolanib had better activity in flt3 
inhibitor-naive patients compared with previously treated patients. Crenolanib was 
also tested against a panel of D835 mutant cell lines and showed superior cytotoxicity 
compared with other available flt3-TKIs such as quizartinib and sorafenib (50, 51).  
Combinatorial therapy represents a solution not only to overcome resistance but may 
enhance efficacy given that results from monotherapy, although promising, are still 
far from optimal. At present, several studies combined quizartinib with conventional 
chemotherapy such as anthracyclines to minimize toxicity (avoiding cytotoxic effects 
resulting from high concentrations of a single agent) and to prompt a synergistic 
effect for better outcome (52).  
In this setting, timing of flt3-TKI delivery is crucial, since flt3L levels dramatically 
increase in response to cytotoxic chemotherapy (53) and this might counteracts flt3-
TKI efficacy (2, 47, 52).  
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        Fig.4:  Quizartinib chemical structure (www.kinasepro.wordpress.com) 
 
 
         
Flt3 signaling in skeletal muscle 
 
A novel role for flt3/flt3L outside of the hematopoietic system has recently been 
reported in skeletal muscle. In this study using C2C12 myoblasts, flt3L was found to 
drive myogenesis. Specifically, these authors described a negative effect on myotube 
formation following flt3 or flt3L knock-down, which was partially rescued by 
exogenous flt3L delivery. They further showed that depletion of flt3/flt3L led to an 
increase in cell proliferation, and proposed that the absence of flt3/flt3L prevented 
cell cycle exit, which is required for promoting differentiation. Finally, in a skeletal 
muscle regeneration model, flt3L mRNA was increased during the early phases of 
regeneration and flt3L siRNA inhibited regeneration, supporting a role of flt3/Flt3L in 
muscle regeneration in vivo (54). These findings are in agreement with an earlier 
study, which showed inhibition of proliferation of muscle-derived stem cells in the 
presence of flt3L through an increase in the length of the cell cycle (55).   
Together, these papers point to a so far unrecognised role of flt3/flt3L in the 
regulation of skeletal muscle precursors. Whereas this novel role is distinct from the 
known role of flt3L as pro-proliferative agent in the permissive growth of B-cell 
precursors (34) and hematopoietic progenitor cells (28, 29, 38), it is consistent with 
the recently reported instructive role of flt3L in early lineage commitment of 
lymphoid/myeloid progenitor cells (33), supporting the notion that flt3 may regulate 
cell fate in a cell type-specific manner.  
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Flt3 signaling in the heart 
 
Flt3 receptor and flt3L expression have been identified in whole heart homogenates in 
mice (56). Interestingly, mRNA levels of flt3L and Flt3 were up regulated between 3 
and 7 days after MI. A recent study suggested that co-administration of exogenous 
flt3L with G-CSF into the peripheral circulation improves post-MI remodelling and 
LV systolic function. They supported the idea that, at least in part, the beneficial 
effect of this treatment was related to increased homing of BM-derived cells into the 
infarcted heart, which differentiate into newly formed myocytes and vascular cells 
(57). 
Flt3L also exerts cytoprotective effects in the injured heart when administered 
exogenously at therapeutic concentrations. In 2014 Pfister et al. identified expression 
of flt3 by intrinsic cardiac cells, which was pronounced in CMCs exposed to hypoxia. 
Flt3 activation triggered by exogenous flt3L decreased CMC apoptosis in vitro and in 
the infarct border zone in vivo and ameliorated post-MI function and remodelling by 
limiting infarct size. The investigators also provided evidence for activation of pro-
survival pathways involving Bcl-2 family protein regulation and inhibition of the 
mitochondrial death pathway (3), as it was previously shown for flt3-expressing 
leukemia cells (58). 
Wang and colleagues examined the effect of flt3L in mice with multi-organ 
dysfunction syndrome, which affects different organs of the body, including the heart. 
They observed mitigated organ damage in the mice treated with flt3L as compared to 
control, an effect, which they attributed to a more favourable immune response in the 
flt3L group (5 µg/kg once a day for seven days) (59). 
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Chapter 2. Cardiac progenitor cells  and regeneration 
 
The adult mammalian heart has an extremely limited capacity to regenerate. Under 
homeostatic conditions, CMC turnover amounts to approximately 0.5-1.5% per year 
(60-62). Although multiple studies have demonstrated that renewal of CMCs based on 
complete cell cycle re-entry of pre-existing CMCs including karyokinesis and 
cytokinesis occurs in areas adjacent to myocardial injury, this is not sufficient to 
replenish the CMC pool and confer recovery of the necrotic, akinetic myocardium (61, 
63-65). The discovery of cardiac progenitor cells (CPCs) opened new perspectives for 
therapeutic cardiac regeneration, aiming at activation of residential CPCs to 
proliferate and differentiate into CMCs and other cardiac cell types (66). 
CPCs are multipotent as they can differentiate into all three main cardiac lineages: 
CMCs, endothelial cells and smooth muscle cells (SMCs). In vitro, they can self-
renew to maintain a pool of undifferentiated clones (66). Such CPCs reside in the 
heart, which allows direct targeting of these cells, thereby circumventing problems 
like poor engraftment or immune rejection that accompany cell transplantation. CPCs 
are activated in vivo in response to cardiac injury to renew and maintain an 
undifferentiated cell pool (67). Numerous preclinical studies have shown that CPCs, 
either endogenously or upon in vitro expansion and transplantation, improve cardiac 
remodelling and function after cardiac injury (61, 68-70).  
Interestingly, an impairment of the CPC pool is observed under anthracycline therapy, 
possibly contributing to chemotherapy-induced cardiomyopathy (71, 72). Specifically, 
administration of doxorubicin (DOXO) in rats has been shown to lead to dilated 
cardiomyopathy via a process that involves CPC alterations. DOXO promoted 
oxidative stress resulting in a dose-dependent reduction of CPC viability along with 
increased apoptosis and premature senescence. Administration of CPCs following 
anthracycline therapy ameliorated the DOXO-induced cardiomyopathy by 
regeneration of cardiomyocytes and vascular structures, which improved cardiac 
function and decreased animal mortality (72). These data propose that the 
functionality of CPCs is important to maintain cardiac cellular homeostasis and that 
weakening of CPC function can contribute to chemotherapy-induced cardiomyopathy. 
This notion is supported by major findings in human CPCs (hCPCs). In this study, the 
majority of hCPCs of DOXO-induced cardiomyopathic human hearts showed signs of 
senescence. Isolated hCPCs under DOXO showed increased apoptosis and DNA 
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damage due to accumulation of reactive oxygen species. DOXO also negatively 
affects hCPC differentiation into CMCs, smooth muscle cells and endothelial cells, 
suggesting a decline in regenerative capacity (71).  
Another cardiac disease, in which functional alterations of progenitor cells have been 
implicated, is diabetic cardiomyopathy (DCM). DCM consists of a progressive 
structural and functional remodelling of the heart in diabetes, which occurs 
independently from coronary atherosclerosis and hypertension, and which eventually 
leads to HF. In a streptozotocin rat model following MI through coronary ligation, 
progenitor cell homing was markedly inhibited in hyperglycemic rats compared to 
normoglycemic rats. As expected, hemodynamic measurements showed that cardiac 
function was much more aggravated in diabetic rats following MI (73).  
 
Different types of potential resident CPCs have been identified so far (74). C-kit+ 
CPCs and cardiosphere-derived cells have been widely explored and recently used for 
autologous transplantation in patients with ischemic cardiomyopathy. In both studies, 
intracoronary CPC transplantation was safe with no incidence of malignant 
arrhythmias or sudden cardiac death.  
Briefly, the c-kit+ Stem Cell Infusion in Patients with Ischemic Cardiomyopathy 
(SCIPIO) trial (in which from a total of 20 patients enrolled in the treated arm, the 
analysis of cardiac MRI data were carried out in 9 treated patients) showed an 
improvement in LVEF at 4 and 12 months after transplantation, along with a 
reduction of the infarct size in a subset of patients. The most dramatic change instead 
was observed in the non-viable LV tissue, which was reduced by 50% after 12 months 
(75).  
Similarly, in the intracoronary CArdiosphere-Derived aUtologous StemCElls to 
reverse ventricUlar dySfunction (CADUCEUS) trial, cardiac MRI did not show any 
change in global function at 1 year after cell delivery, but it revealed a reduction of 
the scar size, which correlated with a consistent 20% increment in viable mass 
compared to control patients (76).  
Despite the significant reduction in myocardial scar mass in both studies and 
significant improvement in cardiac function and patient symptoms in SCIPIO, these 
results have to be taken with the great caution and placebo-controlled, double-blinded 
studies are needed. As in most preclinical studies showing low cardiomyogenic 
differentiation of administered CPCs, the mechanism of action remains unclear, and 
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paracrine effects appear more likely than true cardiomyogenesis.  
In 2003, Oh et al. were the first to isolate Sca1+ CPCs from the adult mouse heart, 
which were negative for blood cell lineage markers, c-kit, flt1, flk1, CD34, and CD45, 
but expressed cardiac transcription factors such as Gata4, MEF2C and TEF-1. In vitro, 
these cells could express α-sarcomeric-actinin and cardiac troponin I upon stimulation 
with the demethylation agent 5-azacytidine. Labelled cardiac Sca1+ cells were 
injected after ischemia reperfusion injury. After 2 weeks, persistence of grafted cells 
was below 1% but donor-derived α-sarcomeric-actinin+ cells were abundant in the 
infarct border zone (68). In addition, murine cardiac Sca1+ cells treated with oxytocin 
differentiated in mature CMCs, with spontaneous beating, well-organized structures 
and electrical junctions (77). More recently, a study confirmed the intrinsic capacity 
of murine cardiac Sca1+ cells to give rise to endothelial cells, which was impaired 
during certain anti-cancer treatments such as DOXO (78).  
An additional purification strategy takes advantage of the ability of CPCs to 
efficiently efflux vital dyes such as Hoechst through specific membrane ATP-binding 
cassette (ABC) transporters, including Abcg2 and Mdr1. ABC transporters utilize the 
energy of adenosine triphosphate (ATP) hydrolysis to carry out certain biological 
processes including translocation of various substrates across membranes such as 
cytotoxic compounds and therapeutic drugs (79).  
These cells, firstly isolated in adult murine BM, showed a low Hoechst fluorescence 
and were referred to as side population (SP) as they fell to the “side” of the bulk of 
the positively stained cells in FACS analysis plots. The ability to efflux Hoechst was 
abolished by the presence of the ABC transporter inhibitor Verapamil, which 
confirmed that these cells are uniquely low in Hoechst fluorescence because of Mdr 
or a Mdr-like-mediated efflux of the dye (80) (Fig 5). 
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Fig.5: Cardiac Side Population.  
 
Since this original discovery, SP-CPCs have been identified in a variety of tissues 
including umbilical cord blood (81), skeletal muscle (82-84), mammary glands (85-
87), lung (88-90), liver (91), epidermis (92, 93), forebrain (94), testis (95, 96), kidney 
(97), limbal epithelium (98, 99), prostate (100), and endometrium (101). In normal 
tissues SP cells express high levels of stem-like genes and possess multipotent 
differentiation potential, and as such, they are thought to behave in a similar fashion 
to stem cells. 
Hierlihy provided the first evidence that the adult myocardium contains a resident 
stem-like cardiac SP (CSP) (102). SP-CPCs localize ubiquitously in the four heart 
chambers mainly in perivascular areas and in interstitial space between CMCs (103) 
and the presence of this heterogeneous population within the adult heart was further 
confirmed in several studies. SP-CPCs were largely negative for hematopoietic 
markers CD45, CD34, and CD44 but exhibited expression of CD31 and Sca1. 
Notably, whereas the well-characterized BM-SP cells additionally expressed the SCF 
receptor c-kit, SP-CPCs were negative for it (5). Furthermore, they demonstrated that 
among Sca1+ SP-CPCs, the greatest potential for cardiomyogenic differentiation is 
restricted to cells negative for CD31 expression. Monoculture of Sca1+/CD31- SP-
CPCs exhibited expression of the early cardiac transcription factor Gata4 and 
contractile protein α-sarcomeric-actinin and troponin I, although an organized 
structure and so a functional maturity was missing. Cellular coupling with neonatal rat 
ventricular myocytes was required to reach further biochemical and immune-
histochemical features of mature CMCs, such as sarcomere organization and 
electromechanical coupling (Fig.6) (5). 
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Fig.6: GFP-expressing Sca1+/CD31- CSP cells (green) co-cultured with adult CMCs:  CSP cells 
(green), α-sarcomeric-actinin (red), dapi/nuclei (blue) (5).  
 
 
In 2005 Oyama et al., observed CSP cell differentiation capacity also in a rat model. 
SP-CPCs were isolated from neonatal hearts, which contained a larger amount of SP-
CPCs compared to an adult heart. When treated with oxytocin, a small proportion of 
SP-CPCs expressed contractile proteins such as α-sarcomeric-actinin and showed 
spontaneous beating. When transplanted in a MI rat model via the tail vein, these cells 
migrated and homed to the injured region of the heart abounding in the border zone 
and contributing to cardiac regeneration (103).  
Subsequently several groups assessed the endothelial differentiation potential of 
murine CSP. Yoon et al. observed that after treatment with vascular endothelial 
growth factor (VEGF) for 28 days, SP-CPCs demonstrated morphological changes 
and differentiated into endothelial cells, which were positively stained for CD31 and 
von Willebrand factor (vWF). Transplantation of these cells into the ischemic thigh 
muscle area showed a greater ratio of ischemic/normal hindlimb blood flow compared 
to the saline-treated group (104).    
A further investigation confirmed Sca1+/CD31+ SP-CPCs as the sub-fraction with the 
highest potential to migrate in the injured region of the myocardium and form a 
vascular tube-like structure (105).  
Liang et al. were the first to prove Sca1+/CD31- CSP progenitor cell commitment in 
vivo following MI. A proportion of these cells, transplanted into non-infarct 
myocardium, expressed myogenic and endothelial markers and participated in 
regeneration of the ischemic areas, although at a minimal rate due to a still incomplete 
differentiation. They proposed a model in which SDF-1α induces chemotaxis of 
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Sca1+/CD31- SP-CPCs to the infarcted area via CXCR4 receptor, which is up-
regulated in Sca1+/CD31- SP-CPCs of ischemic hearts (106).  
Recently the group turned its interest on the characterization of the Sca1-/CD31- CSP 
sub-population. These cells, expanded in vitro, were injected in the mouse heart 
following experimental MI. In a similar way to Sca1+/CD31- SP-CPCs (106), this 
cells, upon injection in a non-infarcted area could migrate from to the injured region 
and form tube-like structures positive for the endothelial marker vWF (107).  
An intense work to understand the origin and potential of SP-CPCs was carried out by 
Noseda et al. Within the Sca1+ CSP, they identified a stricter profile, in which 
PDGFRα-positivity demarcates the clonogenic cardiogenic progenitor cells. They 
assessed tri-lineage differentiation capacity of expanded SP-CPCs in a murine MI 
model. Although cell retention already declined to 0.1–0.5% at 2 weeks, after 12 
weeks 50% of the donor-derived cells were expressing troponin I and 5-15% were 
positive for vascular markers. Of note and new, multipotential properties were 
assessed on a single cell progeny clone expanded and labelled in vitro prior to 
injection (Fig.7). 
                       Fig.7: Cloned cardiac SP cells show tri-lineage potential after cardiac grafting (69).  
 
Via Cre/lox fate mapping, they evaluated the potential origin of SP-CPCs. As all 
cardiac cells, they have a mesodermal origin as they derived from Mesp1+ precursors. 
No CSP cell was derived from pre-existing myocytes. Although Nkx2.5 and Isl1 were 
expressed rarely in fresh single cells and cloned cardiac SP cells, they largely 
contributed to the fate map profile, suggesting that CSP cells originate from Nkx2.5+ 
and Isl1+ precursors, contributors to the epicardium, the first and the second heart 
field (69).     
Despite this considerable amount of work already performed on CPCs, overall 
understanding of CPC biology and behaviour is still insufficient to judge their 
therapeutic potential through either endogenous stimulation or transplantation.  
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Chapter 3. Myocardial infarction 
 
MI is the leading cause for the development of CHF. MI occurs when the blood flow 
to the heart falls below a certain threshold due to a coronary artery blockage and it 
manifests as sudden and dramatic loss of contractile heart muscle cells that are later 
replaced by a fibrotic scar. A sophisticated inflammatory response and adaptive 
mechanisms initiate repair and remodeling processes aimed to compensate for the loss 
of myocytes, and maintain heart elasticity and cardiac function to pump sufficient 
blood to meet the need of the body.  
Repair of the infarcted heart evolves in three overlapping phases: the inflammatory 
phase; the proliferative phase; and the maturation phase (108).   
During the inflammatory phase, acute CMC necrosis (with subsequent release of all 
cellular components in the circulation) and matrix damages generate endogenous 
signals transducing an intense inflammatory response in the infarcted heart. Release 
of endogenous danger associated molecular patterns by ruptured cells promotes the 
activation of the complement cascade and activation of innate immune cells by 
binding to patter recognition receptors as toll-like receptors expressed by 
macrophages, DC cells and neutrophils (109-111). Reactive oxygen species are also 
important contributors to inflammatory signals in the infarcted myocardium during 
the acute phase. All these mechanisms trigger a diffuse chemokine and cytokine 
expression and secretion by several cellular populations (immune cells, fibroblasts, 
smooth muscle cells, endothelial cells), which contribute to a chemotactic gradient to 
recruit leucocyte populations within the first 24 hours (112). In particular, pro-
inflammatory cytokines such as tumor necrosis factor, IL-1β and members of the IL-6 
family are important regulators in protecting surviving CMCs at remote and boarder 
zones from apoptosis and inducing the synthesis of endothelial adhesion molecules 
and leukocyte integrin activation that ultimately lead to the extravasation of 
inflammatory cells into the infarct zone (113). Recruited neutrophils participate in the 
maintenance of a chemotactic gradient over time during the inflammatory phase and 
initiate the release of matrix metalloproteinases, which degrade the inter-myocyte 
collagen struts while monocytes and macrophages remove dead cells and matrix 
debris by phagocytosis (114, 115). Due to these processes, the region is more bound 
to distension, and consequently, more susceptible to deformations. Therefore, CMCs 
may slide on the infarcted wall resulting in wall thinning and ventricular dilation. 
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CMC lengthening may as well contribute to this deformation process, which further 
drives myocardial disarray (116). 
Timely suppression of the inflammatory phase is pivotal to avoid accentuated cardiac 
damage and dysfunction. The repression of pro-inflammatory signaling is not a 
passive process, but requires an induction of inhibitory molecules and an activation of 
suppressive pathways (such as TGF-β, IL-10, pro-inflammatory-resolving lipid 
mediators, which inhibit matrix degradation) (117-120). In this context, macrophages 
acquire an inhibitory profile and phagocytize apoptotic neutrophils (121, 122). Also, a 
pericyte coat of new vessels stabilizes the vasculature and prevents the recruitment of 
leukocytes. Prolonged inflammatory signaling is detrimental: the continued secretion 
of proteases and cytokines by immune cells enhances matrix-degrading processes and 
loss of CMCs resulting in worsening of chamber dilation, loss of ventricular wall 
integrity and, hence, suppression of systolic function.  
The suppression of the inflammatory phase overlaps with the activation of a pro-
fibrotic repair program. Once the wound is cleared from dead cells and matrix debris, 
growth factors released by mononuclear cells and macrophages (such as TGF-β) 
promote activation of mesenchymal reparative cells such as vascular cells, which 
contribute to neovasculogenesis and angiogenesis to the infarcted boarder zone and 
interstitial and perivascular fibroblasts, which trans-differentiate into myofibroblasts. 
Myofibroblasts secrete matrix proteins (mainly type I-III collagen) for the formation 
of a collagen-based scar aimed to preserve structural integrity of the ventricular wall, 
despite the loss of muscle elasticity (108). 
These alterations in ventricular structure are detrimental in the long run, eventually 
leading to symptomatic or asymptomatic ventricular dysfunction and, hence, to HF 
(Fig.8). 
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Fig.8: Myocardial post-MI remodelling.  
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Aim of the study 
 
As in other organs, cardiac homeostasis defines any process involved in regulating 
and maintaining an internal steady state that makes the cells or the organ healthy.  
This work is aimed to understand potential heart damages and disturbance of cardiac 
homeostasis deriving from TK-mediated inhibition of the flt3 receptor in a context of 
treatment of different malignancies, including AML. Flt3 is a cytoprotective system in 
the heart (3) and given that intrinsic, i.e. cardiac, flt3 activation is beneficial for CMC 
survival under ischemic conditions, the blockade of this signaling pathway might lead 
to CMC injury, resulting in cardiac dysfunction. In addition, flt3 is a regulator of 
hematopoietic progenitor cell proliferation and differentiation and may similarly be 
required for the regulation of cardiac progenitor cells. 
For the current study we take advantage of two mouse models: a flt3L-/- model, in 
which we have the complete ablation of flt3 signaling since the embryonic stage and a 
time-defined (and partial) pharmacological inhibition of flt3 signaling via delivery of 
the TKI quizartinib. 
Since Flt3/flt3L is an important regulator of progenitor cell function in different 
organs (1, 54, 123), in the first part of the project, we want to evaluate if and how flt3 
signaling inhibition impacts on the progenitor cell pool of the heart, focusing on a 
specific multipotent CPC population, known as CSP. 
In the second part of the project we want to investigate how endogenous flt3L 
ablation affects the structure and function of the heart at the whole organ level in a 
context of cardiac health and of ischemic disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 		 29	
Materials and Methods  
 
Animals and in vivo models 
Studies were conducted on 8-13 weeks-old C57BL/6NRj (wt), C57BL/6Flt3ltmlImx 
(flt3L-/-) (kindly provided by Prof. Aleksandra Wodnar-Filipowicz), 129S/SvEv-
Flt3tm1Irl (flk2-/-) and C57BL/6-Tg(UBC-GFP)30Scha/J (kindly provided by 
Experimental Hematology research lab (Prof. Radek Skoda) (124).  Flt3L-/- and   
flk2-/- mice were previously described by the original source laboratory (30, 31).  The 
breeding and the animal care was carried out by the DBM Animal Facility 
Hebelstrasse (Basel, Switzerland). 
 
Genotyping 
A 0.5 cm tail biopsy was digested with lysis buffer (TRIS HCl 8.5pH + Proteinase K 
(Thermoscientific, #EO0491)) ON at 56°C. The lysate was centrifuged (2min, max 
speed, RT) to remove debris. DNA samples were heated at 95°C and used for PCR 
(see program below). 2% agarose was polymerised in TAE buffer (40mM Tris acetate 
and 1mM EDTA, pH 8.0-8.5) with Red Safe (Intron Biotech., #21141) addition. PCR 
products were then run for 40min at 100Volt. Bands were visualized with Gel Doc 
XR under UV using BenchTop 100bp DNA Ladder (Promega, #G8291) (Fig.9A-B).  
 
 
 
 
 
 
 
 
 
 
 
Fig.9: A. Genotyping for flt3L on wt and flt3L-/- mice; B. Genotyping for flt3 on wt and flk2-/- mice. 
 
Quizartinib model: 2mg/ml of powdered quizartinib (Selleckchem, #S1526) was 
formulated in 15% polyanionic beta-cyclodextrin Captisol (Cidex pharmaceuticals) 
and administrated via oral gavage once daily. 48 wt mice were included in this 
wt		flt3L-/-		ladder	
5X FIREPol Master Mix   2µl 
(Solis BioDyne, 04-12-00115)  
Primer FOR (10µM)  0.5µl 
Primer REV (10µM)  0.5µl 
ddH
2
O    6µl 
Tot    9.µl/tube 
    + 1µl DNA 
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2 min  94°C 
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30 sec 60°C 
1 min 72°C ßstep2   37 cycles 
10 min  72°C    
∞    4°C 
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experiment. 24 mice (quizartinib-treated) were treated with quizartinib 10 mg/kg/day 
and 24 mice were treated with Captisol only (vehicle-treated) for 28 consecutive days. 
2D-echocardiography was performed on 12-week-old wt 1 day before (baseline) and 
28 days after quizartinib treatment as described. Body weight changes, physical 
condition and behaviour were monitored daily. Following treatment mice were 
subjected to echocardiography and then sacrificed for histology or CSP analysis (see 
below). Heart weight was assessed based on the ventricular weight/tibia length ratio. 
 
Myocardial infarction (MI) model: Baseline 2D-echocardiography was performed on 
7-week-old wt and flt3L-/- mice, 1 week before MI. Wt and flt3L-/ were randomly 
assigned to sham or permanent LAD ligation. Anaesthesia for surgery was performed 
via intraperitoneal administration of ketamin/xylazine/acepromazin (65/15/2 mg/kg) 
and maintained with isoflurane 1-3%. Following left lateral thoracotomy at the fourth 
left intercostal space, MI was induced via permanent ligation of the left anterior 
descending (LAD) (125, 126). Sham-operated mice underwent an identical procedure 
except for LAD occlusion. Buprenorphin 0.1mg/kg in 0.9% NaCl solution was 
applied subcutaneously (s.c.) at the time of surgery, with subsequent additional s.c. 
doses every 6h after surgery and per os (buprenorphin 0.3 mg/ml (5ml) in 160 ml 
drinking water) over-night (ON) for two consecutive days. Body weight changes, 
physical condition and behaviour were monitored daily. Echocardiography was 
performed 1 week post-MI or post-sham and then mice were sacrificed for histology. 
Heart weight was assessed based on the ventricular weight/tibia length ratio. 
 
Echocardiography: Transthoracic echocardiography was performed using a 40 MHz 
probe and the Vevo 2100 Ultrasound machine (VisualSonics, Toronto, ON, Canada). 
Mice were put under isoflurane anesthesia via a nose cone (2% in 100% oxygen) and 
placed on a heated platform to maintain body temperature at 37°C. Hair was removed 
from the chest with a depilatory agent (Nair). The heart was imaged in parasternal 
short and long-axis views both in 2D (B-mode) and M-mode. Data were transferred to 
an offline computer for analysis by an investigator blinded for animal group 
assignment. Left ventricular wall thickness and internal diameters were derived from 
M-Mode tracings acquired in a short axis image plane. Values were averages from 
three separate measurements. Left ventricular ejection fraction (EF) was calculated 
from derived volumes, which are computed based on the 'cubic' equations 
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(EF%=100%×[(LVID;d)3-(LVID;s)3)]/(LVID;d)3). Echocardiographic 2D strain and 
strain rate measurement based on speckle-tracking was used to assess the global 
changes of left ventricular function. 
 
Perfusion and paraffin embedding 
350mM KCl (in water) was intravenously (jugular vein) injected to block the heart in 
diastole. The mouse chest was opened with scissors. A small cut was produced on the 
right atrium and a 29G needle was placed longitudinally into the apex of the LV. The 
heart was then perfused with 15 mL of cold 4% paraformaldehyde (PFA) under 
controlled pressure (70-90 mmHg). After removing the atria (and the right ventricle 
for some experiments), the perfused hearts were cleaned from surrounding non-heart 
tissue and left ON at 4°C in 4% PFA. The hearts were then transferred to 70% EtOH 
and cut transversally into three pieces (apex, middle, basis) using a sterile razor blade 
and processed for paraffin embedding. The embedded tissue was cut in 4µm sections 
on a Microm HM 340E Microtome and used for histology.  
 
Immunohistochemistry  
- von Willebrand factor (vWf), Wheat germ agglutinin (WGA), α-sarcomeric-actinin, 
Isolectin B4 (IB4) staining: 
Tissue was deparaffinised and rehydrated. Tissue was then processed for antigen 
retrieval using Antigen Unmasking Solution (Vectorlabs, #H3300) at 97°C for 25min 
or using Proteinase K 20 mg/ml (Thermoscientific, #EO0491) for 25min. Tissue was 
washed with Tris-Buffered Saline Tween and blocked with 10% goat serum (Life 
Technologies, 50-062Z) for 1h. Immunostaining was performed using the following 
antibodies: vWf (1:50 Abcam, #6994), FITC-labelled WGA (1:100 Sigma, #4895), α-
sarcomeric-actinin (1:20 Sigma, #A7811), DyLight 594 labelled IB4 (1:25 Vector 
labs, #DL-1207). Goat Alexa Fluor (Invitrogen) (1:100 to 1:800 according to primary) 
was used for secondary detection. Secondary antibody only was used as a negative 
control. 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen, #D1306) was used to 
stain cell nuclei. Tissue was mounted with SlowFade Antifade kit (Invitrogen, 
#S2828). The stained samples were visualized using Widefield Fluorescence 
Olympus BX63 or Olympus BX61 and quantified with CellSens software (Olympus).  
- TUNEL staining: 
Tissue was deparaffinised and rehydrated. Tissue was then processed for antigen 
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retrieval using Antigen Unmasking Solution (Vectorlabs, #H3300)  at 97°C for 25min. 
Tissue was washed with phosphate buffered saline (PBS) and incubated 2h at 37°C 
with In situ cell death detection kit, Fluorescein (Roche Diagnostics AG, #12-156-792-
910). DAPI was used to stain the nuclei. Tissue was mounted with SlowFade Antifade 
kit. 
The stained samples were visualized using Widefield Fluorescence Olympus BX63 or 
Olympus BX61 and quantified with CellSens software (Olympus).  
- Fibrosis staining:  
Tissue was deparaffinised and rehydrated. Tissue was treated 15min with preheated 
Bouin’s solution (Sigma, #HT10132-1L) at 56°C and washed with running water. 
Tissue was subsequently treated with Weigerts iron Hematoxylin solution (Sigma, 
#HT1079) Biebrich Scarlet-Acid Fuchsin and Phosphotungstic/Phosphomolybdic acid 
solutions (Thricrome staining (Masson) kit, Sigma #HT15), respectively for 5, 5 and 
20min, with washing in running water for 5min in between. 
Then tissue was treated 10min with Aniline Blue Solution (Sigma, #HT15), 2min in 
1% Acetic Acid (Sigma (Fluka), #45731) and rinse again in water. Tissue was then 
dehydrated and mounted with Cytoseal 60 (Thermoscientific, #8310-4) 
 
Cardiac Side Population Isolation and Pyronin Y staining  
SP-CPCs was isolated as previously described with some adjustments (4). 12-week-
old mice were euthanized with 200mg/kg Pentobarbital i.p.. The heart was removed 
from the chest, minced with a razor blade and digested with Collagenase B 1mg/ml 
(Roche Diagnostics, #AG 11088807001) and 2.5mM CaCl2 at 37°C for 30min. 
Cardiac suspensions were filtered with 100 and 40µm cell strainers to eliminate 
undigested tissue and mature cardiomyocytes, and further treated with red blood lysis 
buffer (Biolegend, #420301) to deplete erythrocytes. Cardiomyocyte- and 
erythrocyte-depleted cardiac cells were suspended 1million/ml in DMEM (Gibco, 
#31885) supplemented with 10% FBS (Hyclone, #SH30071) and 25mM Hepes  
(Gibco, #15630)  and stained with Hoechst 5µg/ml (Sigma, #B2261)  at 37°C for 
90min in the dark. Cells were washed with Hank's buffered salt solution (HBSS) and 
additionally incubated with Sca1-FITC (0.6 µg/107) (BD, #557405) and CD31-APC 
(0.25 µg/107) (BD, #551262) at 4°C for 30min in the dark. 7-Aminoactinomycin D 
(1µg/107 cells) (Invitrogen, #A1310) was added to the samples to exclude dead cells. 
The Sca1+/CD31- CSP fraction or whole CSP cells were sorted using Influx or 
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Sorpass AriaIII (BD) flow cytometer cell sorters.  
To quantify RNA content of SP-CPCs, Pyronin Y (PY) 2µg/ml (Sigma, #P9172) was 
added for additional 15min after Hoechst incubation at 4°C in the dark. Cell sorting 
was performed by the DBM Flow cytometry Facility (Basel, Switzerland). 
 
RNA sequencing from heart tissue and cardiac side population 
RNA was isolated from a total of five sorts each of wt and flt3L-/- SP-CPCs (from 4 
mice, the cells of which were pooled) or from 10 mg of heart tissue (ground with 
homogenizer using 5mm steel beads after atria removal, n=4 per group) using the 
NucleoSpin RNA XS kit (Macherey Nagel). RNA quality was controlled on an 
Agilent 2100 Bioanalyzer using RNA Pico CHIP (Agilent Technologies). RNA 
concentration was assessed using Quantus Fluorometer (Promega, #E6150) and 
QuantiFluor RNA System (Promega #E3310), a Fluorescence-based nucleic acid 
quantification method (See table 1-2).  
RNA-seq library preparation and sequencing was performed at the Quantitative 
Genomics Facility of the Department of Biosystems Science and Engineering of the 
Swiss Federal Institute of Technology Zurich (Basel, Switzerland).  
RNA-seq libraries from SP-CPC RNA samples were created with the SMART-Seq v4 
kit from Clontech/Takara (1, 2). Sequencing was performed on an Illumina NextSeq 
500 sequencer, and single-end 75bp unstranded reads were produced.  
RNA-seq libraries from heart tissue RNA samples were created with the TruSeq RNA 
Library Prep Kit v2 (starting from 100ng per sample). Sequencing was performed on 
an Illumina NextSeq 500 sequencer, and single-end 75bp stranded reads were 
produced. 
RNA-seq reads were mapped to the mm10 mouse genome assembly, with STAR 
(version 2.5.2a) (3). We allowed at most 10 hits to the genome per read. Reads were 
assigned to the best mapping location, or randomly across equally best mapping 
locations. Using the list of mouse Known Genes coordinates, obtained from 
http://genome.ucsc.edu in December 2015, and the qCount function from the 
Bioconductor package QuasR (version 1.18.0), we quantified gene expression as the 
number of reads that started within an annotated exon of a gene. The differentially 
expressed genes were identified using the Bioconductor package edgeR (version 
3.18.1) (4). Sequencing analysis was performed in collaboration with the DBM 
Bioinformatics Core Facility (Basel, Switzerland). 
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Table1-2: Integrity and concentration values of RNA samples isolated from freshly sorted CSP cells 
(CPC) and heart (WH) homogenates. 
 
Neonatal Rat Ventricular Myocyte (NRVM) Isolation  
Neonatal rat pups were sacrificed by decapitation and hearts were quickly removed. 
Atria were removed and ventricles were transferred into Trypsin EDTA 0.05% (Gibco, 
#25300) over night (ON). 
Hearts were washed with 7ml Medium3 (check below) and then digested with 
collagenase type 2 (36 mg/50ml HBSS) (Worthington, #LS004174). Suspension was 
filtered over a 100µm cell strainer to remove undigested tissue. Cells were suspended 
in Medium3 and pre-plated to remove most of the fibroblasts and endothelial cells 
(2x1h at 37°C). After preplating cells were counted and plated in Medium3 with 
100µM Bromodeoxyuridine (Sigma, #B5002) to prevent proliferation of non-
myocytes.  
 
Culture media     
Sca1+/CD31- SP-CPCs or NRVM were cultured in vitro at 37°C 5%CO2 in: - Medium1 (regular medium for CSP cells expansion): αMEM (Gibco, #32561) 
supplemented with 20% Fetal bovine serum (FBS) (Hyclone, #SH30071), 25 
mM HEPES (Gibco, #15630), 1% penicillin and streptomycin (Gibco, 
#15140) and Sodium Pyruvate (Gibco, #11360).  - Medium2 (regular medium for CSP cells expansion): 35% Iscove’s Modified 
Dulbecco’s Medium (IMDM) (Gibco, #12440), 65% Dulbecco’s Modified 
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Eagle’s Medium (DMEM)/Nutrient Mix F-12 Ham (Sigma #D8437), 3.5% 
FBS (Hyclone, #SH30071), 1.3% B27 supplement (Gibco, #17504044), 6.5 
ng/ml recombinant human epidermal growth factor (EGF) (Peprotech, #AF-
100-15), 13 ng/ml recombinant human fibroblast growth factor-basic (FGF) 
(Peprotech, #100-18B), 0.0005U/ml thrombin (Diagnotec AG, #100-125), 
0.65 ng/ml Cardiothrophin-1 (Peprotech, #250-25), 1% penicillin and 
streptomycin (Gibco, #15140) and 0.2mM Glutathione (Sigma-Aldrich, 
#G6013) (69). - Medium3 (regular medium for NVRM): DMEM low Glucose, Pyruvate 
(Gico, #31885 supplemented with 7% FBS (Gibco, #10270), 25mM HEPES 
(Gibco, #15630), 1% penicillin and streptomycin (Gibco, #15140). - Medium4 (smooth muscle differentiation medium): 35% IMDM (Gibco, 
#12440), 65% Dulbecco’s Modified Eagle’s Medium (DMEM)/Nutrient Mix 
F-12 Ham (Sigma #D8437), 3.5% FBS (Hyclone, #SH30071), 1.3% B27 
supplement (Gibco, #17504044), 10 ng/ml platelet-derived growth factor-beta 
(PDGF-β) (Peprotech, #100-14B), 0.0005U/ml thrombin, 0.65 ng/ml 
Cardiothrophin-1 (Peprotech, #250-25), 1% penicillin and streptomycin 
(Gibco, #15140) and 0.2mM Glutathione (Sigma-Aldrich, #G6013) - EGM-2 Bulletkit (Lonza, #CC-3162) (endothelial differentiation medium): 
Endothelial Basel medium (EBM-2) 500ml, human epidermal growth factor 
(hEGF) 0.5ml, vascular endothelial growth factor (VEGF) 0.5ml, R3-Insulin-
like growth factor (R3-IGF-1) 0.5ml, Ascorbic acid 0.5ml, Hydrocortisone 
0.2ml, human Fibroblast growth factor-basic (hFGF-β) 2ml,  Heparin 0.5ml, 
FBS 10ml, Gentamicin/Amphotericin-B 0.5ml. 
 
Proliferation assay 
1x104 Sca1+/CD31- SP-CPCs (from passages P6-P8) were seeded with Medium1 or 
Medium2 (≈ 500cells/cm2). Proliferation was assessed over 5 days by cell counting 
using Neubauer chamber. Trypan blue was used to exclude dead cells.  
 
Colony formation assay 
100 expanded Sca1+/CD31- SP-CPCs were plated in 3.5cm dishes with 1mL of 
Medium2. Medium was changed every 3 days. At 7, 10 and 14 days cells were fixed 
with 100% ice-cold MetOH for 10min on ice. Cells were then stained with 0.5% 
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crystal violet (1% Cristal violet (Sigma, #V5265):water 1:1) for 10min. Cells were 
carefully washed 5-6 times with water and let dry at RT ON (lid open). 
 
Cardiostem spheres assay 
2x105 Sca1+/CD31- SP-CPCs (P6-P8) were seeded in bacterial dishes (≈ 
3000cells/cm2) in Medium2 (without EGF, FGF). After 24h, 15 cardiostem spheres 
were collected with a pipette tip under the microscope under the flow desk and seeded 
in a LN-coated (10µg/ml) 24well-plate in Medium3. Cardiostem spheres were 
cultured for 2 weeks and medium was changed every 3 days. Expression of cardiac 
markers was assessed by immunocytochemistry (see below). 
 
Immunocytochemistry 
Freshly isolated or expanded SP-CPCs were cultured in non-coated, fibronectin (FN)-
coated (10 µg/ml) or laminin (LN)-coated (10 µg/ml) dishes for 2 weeks with defined 
medium (see above) (FN: Sigma, #F4759; LN: Sigma, #L2020). Cells were washed 
with PBS and fixed in 3.7% PFA for 2-10min at room temperature (RT). Cells were 
then permeabilized with 0.1%-0.3% TritonX (Sigma (Fluka), #93420) in PBS, 
washed with PBS and blocked with 10% goat serum (Life Technologies, #50-062Z) 
for 1h. Immunostaining was performed using the following antibodies: von 
Willebrand Factor (1:100 Abcam, #6994), α-sarcomeric-actinin (1:25 Sigma, 
#A7811), troponinI (1:50 Santa Cruz, #15368), , α- Smooth Muscle Actin (1:50 
Sigma, #A2547). Goat Alexa Fluor antibodies (Invitrogen) (1:500 to 1:800 according 
to primary) were used for secondary detection. DAPI was used to stain cell nuclei. 
Secondary antibody only was used as a negative control. The stained samples were 
visualized using Widefield Fluorescence Olympus BX63 or Olympus BX61 and 
quantified with CellSens software.  
 
Tube formation assay 
3x105 SP-CPCs were cultured in FN- and LN-coated (10 µg/ml) P10 dishes. After 
24h in 0.1% FCS Medium1 (without EGF, FGF, Thrombin, Cardiothrophin-1, and 
B27) cells were cultured in EGM-2 medium for 3 weeks. Medium was changed every 
3 days. Cells were collected and counted. 2x104 SP-CPCs were then cultured in 
Matrigel Basement Membrane Matrix Growth Factor Reduced 10mg/ml (Corning, 
#354230). After 24h we evaluated tube formation capacity. 
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Flow Cytometry  
Expanded Sca1+/CD31- SP-CPCs from passages P7-P9 were cultured in Medium1 or 
Medium2 in 75cm2 flask. After trypsinization cells were washed with HBBS and 
counted using a Neubauer chamber. Cells were incubated for 1h at the dark at 4°C 
using the following conjugated antibodies: Sca1-FITC  (BD, #557405), FITC Rat 
IgG2a, κ Isotype Control (BD, #554688), CD31-APC (BD, #551262), APC Rat 
IgG2a κ Isotype Control (BD, #553932). After washing with HBBS,                          
7-Aminoactinomycin D (1µg/107 cells) (Invitrogen, #A1310) was added to the 
samples to exclude dead cells. Samples were analysed with BD Fortessa. 
 
RNA interference 
1x105 SP-CPCs were seeded in Medium1 (-antibiotics) ON. Medium was changed 
and cells were transfected with 40nM siRNA_flt3L (Mm_Flt3l_1 Qiagen, 
#SI01003695) or AllStars Negative Control siRNA ( Qiagen, #SI03650318) for 72h 
(new medium with siRNA was added after 48h) using DharmaFECT1 (Dharmacon, 
#T2001) as a vehicle. Cells were collected for RNA or protein extraction using 
Trizol-Chloroform or Lysis/RIPA buffer respectively. 
 
ELISA 
1x105 SP-CPCs were seeded with regular Medium1 (-antibiotics for siRNA 
transfection) or Medium2 ON. Medium was changed every 48h. Supernatant was 
collected after 96h and centrifuged using Amicon Ultra-4 Centrifugal Filter Units 
(Millipore, #UFC801024) to achieve a retention volume of  ≈150 µl.  
Flt3L abundance in supernatant was detected using mouse Flt3 Ligand ELISA kit 
(R&Dsystems, #MFK00) and quantified by ELISA reader at delta 450-540nm. 
Concentrated medium only was used as blank.  
For siRNA treatment Medium1 was substituted by phenol-free DMEM without FCS 
and antibiotics during the last 48h of culturing. 
 
In vitro flt3L treatment for western blot  
Wt, flt3L-/- and flk2-/- SP-CPCs were seeded and expanded in Medium1 or Medium2 
till 90% confluence. Cells were then kept at 0.1% FCS ON. Cells were treated 5min 
with flt3L (R&Dsystems, #427-FL/CF) 100ng/ml and Akt phosphorylation was 
quantified by Western Blotting (see below). To evaluate the quizartinib inhibitory 
 		 38	
effect on flt3L-dependent Akt phosphorylation, CSP cells were preincubated for 2h 
with 5nM DMSO diluited-quizartinib (Selleckchem, #S1526) prior to flt3L treatment. 
DMSO only was used as negative control. 
 
Polymerase Chain Reaction (PCR)  
RNA was extracted from expanded SP-CPCs using Trizol-Chloroform (Sigma) or 
Direct-zol RNA MiniPrep Plus (Zymo Research, #R2072) and cDNA was generated 
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
#4368814) (see program below). Normal PCR was performed using FIREpol Master 
Mix (Solis BioDyne, #04-12-00115) to assess expression of stemness, 
cardiomyogenic and vascular genes. Quantitative Real Time (RT-PCR) was 
performed using Power SYBR Green PCR Master Mix (Applied Biosystems, 
#4367659). Samples were run and expression was quantified Fast 7500 Real Time 
PCR systems. 
 
Reverse transcriptase PCR:  
 
 
 
 
 
Normal PCR:  
 
 
 
 
 
 
To evaluate gene expression the following primers were used: 
Gene Forward   5’- 3 Reverse   5’ – 3 Cycle Nr. 
Pou5f1 GGAGTCCCAGGACATGAAAGC TGCTGTAGGGAGGGCTTCG 38 
Nanog GGTGGCAGAAAAACCAGTGG   GCTTCCAGATGCGTTCACC 38 
Klf4 GCCCAACTACCCTCCTTTCC CTGGTCAGTTCATCGGAGCG 30 
c-kit CAGGACCTCGGCTAACAAAGG ACTCTTGCCCACATCGTTGG 38 
Program: 
  
10 min  94°C 
120min 94°C 
5   sec 60°C 
∞    4°C 
RT-Buffer   2.0 µl 
dNTP    0.8 µl 
Random Primer   2.0 µl 
Reverse Transcriptase  1.0 µl 
RNasin (Promega, #N211B) 0.5 µl 
H2O    3.7 µl   
   + 10 µl  (up to 2 µg) RNA 
Program: 
  
2 min  94°C 
30 sec 94°C 
30 sec 60°C 
1 min 72°C ßstep2   25/30/38 cycles 
10 min  72°C    
∞    4°C 
5X FIREPol Master Mix   2µl 
(Solis BioDyne, #04-12-00115)  
Primer FOR (10µM):  0.5µl 
Primer REV (10µM):  0.5µl 
ddH
2
O:    5µl 
Tot    8.µl/tube 
   + 2µl cDNA (50ng) 
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Nkx2-5 CCTGACCCAGCCAAAGACC CACTTGTAGCGACGGTTCTGG 38 
Gata4 GCCAACCCTG GAAGACACC TTGCAAGAGGCCTGGGAA 38 
Myh6 GCCGTATCATCACCAGAATCC   TCCAGCCTCTCGGTCATCTC 38 
Actn2 AGGCCATGCAGAAGAAGCTG GTCAGGGTCGCAGACTCGTAG 38 
Tnni3 CTGCCAACTACCGAGCCTATG CCCTCAGGTCCAAGGATTCC 38 
Gapdh CAGAACATCATCCCTGCATCC AGGTCCACCACCCTGTTGC 38 
flt3L (DNA) GCCCAAATGTGCGTATACCT CCCAGCACAGTATGGGAACT 38 
flt3 rec (DNA) CGT TGT TCC CTC TAC CTC AC AATCAAAGTGCGGCTGGC 38 
 
 
Real Time PCR 
 
 
 
 
 
 
To evaluate gene expression the following primers were used: 
Gene Forward   5’- 3 Reverse   5’ – 3 
Nanog GGTGGCAGAAAAACCAGT GG GCTTCCAGATGCGTTCACC 
Nkx2-5 CCTGACCCAG CCAAAGACC ATCCGTCTCGGCTTTGTCC 
Gata4 GCCAACCCTGGAAGACACC GACATGGCCCCACAATTGAC 
Myh6 GCCGTATCATCACCAGAATCC   TGGATAACCAGCAGGGCATC 
Actn2 TTGGAGCACTTGGCTGAGAAG GTCAGGGTCGCAGACTCGTAG 
Tnni3 CTGCCAACTACCGAGCCTATG CGTTCCATCTCCTGCTTCG 
Tie2 TGCCCTCCTGGGTTTATGG GGTCCTGCCAAATGTGTGC 
Vwf GATGGAGGGGAGCTTGAACTG CGACTCCACCACCTCAAAGTG 
Abcg2 CATGAAACCTGGCCTTAATGC TCCCTTTGGATCTTTCCTTGC 
Abcb1b TCAACTACCCATCGAGAAGCG TTGTGCTTTTTCCACAGCCAC 
Kdr GGGATGGTCCTTGCATCAGAA   ACTGGTAGCCACTGGTCTGGTTG 
Trp63 AAGCAGCAAGTATCGGACAGC  TCATCATCTGGGGATCTCCG 
flt3 rec. 
Probe 
TGGCTCATCAGCGGGAAA 
TCGTACCGAATGGTGCGAGGATCC 
 
GGGGCACACTGGAGGTCTT 
flt3L CACCTCATGTA CCTTCCAGCC GTCTGGACGAATCGCAGACA 
Klf4 CGGAAAAGAACAGCCACCC CTGGTCAGTTCATCGGAGCG 
αSMA GGGAGTAATGGTTGGAATGGG GCCAGATCTTTTCCATGTCGT 
PECAM CGTGAATGACACCCAAGCG CGCAATGAGCCCTTTCTTCC 
Vegfr2 GGGATG GTCCTTGCATCAGAA ACTGGTAGCCACTGGTCTGGTTG 
Rn18s CCATTCGAACGTCTGCCC GTCACCCGTGGTCACCA 
 
Program: 
  
20 sec 95°C 
03 sec 95°C 
30 sec 60°C ßstep2   40 cycles 
∞    4°C 
SYBR Green PCR Mix:  10µl 
Primer FOR (10µM): 0.75µl 
Primer REV (10µM): 0.75µl 
ddH
2
O:   3.5µl 
   10µl/tube 
   + 5µl cDNA  
(cDNA concentration according to the target) 
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Western blot 
Protein samples were prepared from cell lysates and homogenised hearts using Lysis 
or RIPA buffer (Cell Signaling, #9803/9806) containing PhosSTOP (Roche, 04-906-
845-001) and Complete Protease Inhibitor Cocktail (Roche, 11-697-498-001). Protein 
samples were reduced with β-mercaptoethanol or Dithiothreitol and heated at 95°C 
with shaking. Samples were loaded on 10% SDS-Page and run at 120 Volt. Protein 
samples were transferred onto PVDF membranes previously activated with Methanol. 
After blocking 1h with 4% bovine serum albumin (BSA), the immuno-blotting was 
performed using the following antibodies diluted in BSA: Stat5 (1:5000 Cell 
Signaling, #9358), p-Stat5Tyr694 (1:1000 Cell Signaling, #9359), Stat 3 (1:3000 Santa 
Cruz, #482/8019), p-Stat3Tyr705 (1:2000 Cell Signaling, #9145), Akt (1:7000 Cell 
Signaling, 9272), p-AktSer473 (1:2000 Cell Signaling, 4058), ERK (1:7000 Cell 
Signaling, #9102), p-ERKThr202/Tyr204 (1:2000 Cell Signaling, #9101), cyclinB1 
(1:1000 Cell Signaling, #4138), cyclinD1 (1:2000 Cell Signaling, #2926), Tubulin 
(1:7000 Sigma, #T6199), GAPDH (1:10000 Sigma, #G8795). Horseradish 
peroxidase-conjugated secondary antibody (Jackson Immuno Research) was used to 
enhance the binding signal. Western Lightning Plus-ECL Enhanced 
Chemiluminescence (Perkin Elmer, NEL105001EA) was used as substrate to develop 
the membrane in a colorimetric detection. Image SXM software was used to quantify 
protein expression. For multiple staining the membranes were re-blotted with Re-Blot 
Plus Strong Solution (Millipore, #2504). 
 
Data presentation and Statistical Analyses 
Data are presented as mean±SEM. Statistical analyses were performed with GraphPad 
Prism version 7 software (GraphPad). Values were tested for Gaussian distribution 
using the D’Agostino-pearson normality test. If normally distributed, the data sets 
were analyzed using parametric testing. All non-normally distribuited data sets and all 
data sets with n<8 were analyzed using non-parametric testing, as indicated.   
Two groups data sets were compared using unpaired t-test or Mann Whitney test, 
accordingly to parametric or non-parametric distribution. 
For multiple comparison normally distribuited data sets were compared using 
ordinary one-way ANOVA followed by Hold-Sidak post hoc testing; non-normally 
distruibuited data sets were compared using Kruskal-Wallis test followed by Dunn 
post hoc testing. 
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 Results 
 
Chapter 1. Role of flt3 signaling in the regulation of the cardiac progenitor cell 
pool 
 
SP-CPCs express functional flt3 receptor and secrete flt3L  
 
Flt3 receptor is mainly expressed by hematopoietic progenitor cells. In the heart 
CMCs express functional flt3, which is up-regulated in response of oxidative stress 
(3). We therefore examined whether flt3 is also expressed by SP-CPCs. Consistent 
with previous findings in hematopoietic stem cells (38) we could not detect flt3 
receptor expression using flow cytometry, probably due to the low numbers of flt3 
receptor molecules on the cellular membrane (data not shown). Therefore, we verified 
the presence of functional flt3 receptor by exogenously activating intrinsic flt3-
signaling. We treated SP-CPCs with recombinant flt3L and examined the flt3L-
induced phosphorylation of Akt (pAkt), which has been shown to be a canonical 
downstream target of flt3-signaling (127). Following flt3L treatment we observed 
dose-dependent phosphorylation of Akt at 5 min, confirming the expression of 
functional flt3 receptor on SP-CPCs (n=4) (Fig.1A). We also observed Akt-
phosphorylation in response to exogenous flt3L in flt3L-/- SP-CPCs, indicating that 
these cells still preserved receptor function and are responding to flt3L (n=3) (Fig.1B). 
Although to date, only one receptor for flt3L has been identified, we sought to 
exclude Akt-phosphorylation via unspecific mechanisms by treating wt and flk2-/- 
(flt3 receptor KO) SP-CPCs with 100ng/ml flt3L. As expected, flt3L induced Akt 
phosphorylation only in wt but not in flt3 receptor-deficient cells, confirming signal 
transduction through binding of flt3L to the flt3 receptor (Fig.2). These data suggest 
that SP-CPCs are a target of endogenous flt3L in the heart. 
Flt3L is widely expressed in various tissues. In the hematopoietic system, Flt3L is 
secreted by stromal fibroblasts (26, 128) and T cells (129). With respect to cardiac 
cells, we found flt3L secretion by cardiac fibroblast (data not shown). We therefore 
tested whether SP-CPCs also secrete flt3L. We collected the supernatant from 
expanded SP-CPCs and were able to detect secretion of flt3L in wt SP-CPCs, whereas 
flt3L was absent in the supernatant from flt3L-/- CSP cultures. In addition, down-
regulation of flt3L gene expression via siRNA treatment (siflt3L) resulted in 
significant reduction of flt3L secretion by wt SP-CPCs (n=3) (Fig.3).  
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In addition to being flt3L target cells, these data identify SP-CPCs as source of flt3L 
production, suggesting that activation of CSP by flt3L may occur in both an autocrine 
and paracrine fashion Fig.4).  
 
 
 
  
 
 
 
Fig.1: A. Akt phosphorylation in response to recombinant flt3L (0 - 100ng/ml) in expanded wt SP-
CPCs (P7) in α-MEM 20%FCS medium. Representative blots are shown. Statistics: n=4, data are 
shown as mean±SEM, Kruskal-Wallis test, 0 vs. 100 ng/ml **p<0.01; B. Akt phosphorylation in 
response to recombinant flt3L (0 - 100ng/ml) in flt3L-/- expanded SP-CPCs (P7) in α-MEM 20%FCS 
medium. Representative blots are shown. Statistics: n=3, data are shown as mean±SEM. unpaired t-test,  
0 vs. 100 ng/ml  **p<0.01. P7 = passage7        
 
 
 
Fig.2: Akt phosphorylation in response to recombinant flt3L (0 - 100ng/ml)in wt and flk2-/- expanded 
SP-CPCs (P7) in α-MEM 20%FCS medium. Representative blots are shown. n=2, data are shown as 
mean±SEM. P7 = passage7        
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Fig.3: Flt3L in the supernatant from wt and flt3L-/- SP-CPCs (P7), and wt SP-CPCs treated with 
scrambled (si_Ctr) or flt3L-targeted siRNA (si_flt3L) after 48h in α-MEM 20%FCS medium as 
measured by ELISA. n=3, data are shown as mean±SEM. One-way ANOVA, ***p<0.001. P7 = 
passage7.        
 
 
Fig.4: Proposed model of autocrine and paracrine flt3L stimulation of CPCs.  
 
 
Absence of flt3L decreases the cardiac side population in the adult mouse heart 
 
The CSP is a defined population of progenitor cells in the heart. Its size and function 
have to be tightly regulated to maintain cardiac cellular homeostasis and – hence – 
organ integrity. Since flt3 signaling has a major role in regulating hematopoietic 
stem/progenitor cell function, we examined how lack of flt3L affects the CSP in vivo 
and in vitro.  
Flt3L-/- mice show a significant decrease of the CSP compared to age-matched 12 
weeks-old wt mice (1.79% ± 0.21 vs. 1.01% ± 0.23, p<0.05; n=11) (Fig.5A and B), 
and this decrease is accentuated when considering only the distal portion of the tail 
CSP	progenitor 
Cardiac	Fibroblast 
Paracrine	
stimulation 
Autocrine	
stimulation 
*** 
*** 
wt flt3L-/- si_Ctr si_flt3L
0.00
0.05
0.10
0.15
0.20
flt
3L
 (n
g/
m
L)
 		 44	
A	 B	
CB	
(tip CSP), the cells of which possess the most stringent progenitor phenotype (0.023% 
± 0.004  vs. 0.007% ± 0.001, p<0.01; n=11) (Fig.5C).  
The CSP exists as an heterogeneous population. We additionally broke down the CSP 
to isolate the fraction positive in Sca1 and negative in CD31 (Fig.6A), which has the 
highest cardiomyogenic potential (5) and the highest in vitro expansion capacity (69). 
We observed no significant difference of the percentages of this specific 
subpopulation between wt and flt3L-/- mice (0.61% ± 0.18  vs. 1.03% ± 0.26, ns; 
n=7) (Fig.6B).  
To corroborate that our findings are related to the deficieny of Flt3-signaling, the 
same analyses were performed in mice lacking the flt3 receptor (flk2-/-). Similar to 
flt3L-/- mice, we also observed a depletion of the CSP in flk2-/- compared to wt mice 
(1.32% ± 0.19  vs. 0.63% ± 0.13, p<0.01; n=12) (Fig.7A) and this rarefaction is also 
accentuated in the distal portion of the tail (0.023% ± 0.009 vs. 0.011% ± 0.003, 
p<0.01; n=12) (Fig.7B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5: A. CMC- and erythrocyte-depleted population from digested hearts were stained with Hoechst 
and analysed by flow cytometry. Verapamil was used as negative control. Representative flow 
cytometry readouts of the CSP are shown. B. CSP% in the CMC- and erythrocyte-depleted population. 
Statistics: wt vs flt3L-/-, n=11 (pool of 4 mice for each “n”), data are shown as mean±SEM. Unpaired 
t-test, * p<0.05; C. Tip CSP % in the CMC- and erythrocyte-depleted population. Statistics: wt vs 
flt3L-/-, n=11 (pool of 4 mice for each ”n”), data are shown as mean±SEM. Unpaired t-test,  ** p<0.01   
 
         
 
wt flt3L-/-
0.00
0.01
0.02
0.03
Ti
p 
C
SP
 (%
)
Hoechst Red 
H
oe
ch
st
 B
lu
e 
0.021 
1.93 
wt 
0.009 
1.06 
flt3L-/-     
wt flt3L-/-
0.0
0.5
1.0
1.5
2.0
2.5
C
SP
 (%
) * 
** 
0.014 0.018 
+ Verapamil + Verapamil 
 		 45	
A	 B	
A	 B	
C	
 
 
Fig.6: A. CMC- and erythrocyte-depleted population from digested hearts were stained firstly with 
Hoechst, subsequently with Sca1 and CD31 antibodies and then analysed by flow cytometry. 
Representative flow cytometry readouts of the CSP subfractions are shown; B. Sca1/CD31- CSP % in 
the CSP. Statistics: wt vs flt3L-/-, n=7 (pool of 4 mice for each “n”),  data are shown as mean±SEM. 
Mann Whitney test,  not significant (ns.).           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.7: A. CMC- and erythrocyte-depleted population from digested hearts were stained with Hoechst 
and analysed by flow cytometry. Verapamil was used as negative control. Representative flow 
cytometry readouts of the CSP are shown. B. CSP% in the CMC- and erythrocyte-depleted population. 
Statistics: wt vs flk2-/-, n=12 (pool of 4 mice for each “n”), data are shown as mean±SEM. Unpaired t-
test, ** p<0.01; C. Tip CSP % in the CMC- and erythrocyte-depleted population. Statistics: wt vs    
flk2-/-, n=12 (pool of 4 mice for each “n”), data are shown as mean±SEM. Unpaired t-test,  ** p<0.01           
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Quizartinib inhibits flt3 signaling in CPCs in vitro 
 
Quizartinib is a pharmacologic flt3-inhibitor, which exhibits a high binding affinity to 
both wild-type and mutated flt3 and is supposedly more specific for the flt3 receptor 
than previous TKIs (45). We assessed the efficiency of quizartinib to inhibit flt3L-
induced signaling in SP-CPCs in vitro. After 2 hours pre-incubation, quizartinib 
inhibited flt3L-dependent phosphorylation of Akt (Fig.8), confirming the flt3L-
responsiveness of SP-CPCs and the ability of quizartinib to inhibit the ligand-
dependent signaling of wild-type flt3 in these cells. 
 
 
 
 
 
 
 
 
Fig.8: Flt3L (100ng/ml) treatment of wt SP-CPCs pre-treated with the flt3-inhibitor quizartinib (diluted 
in DMSO) or DMSO alone. Representative blots are shown. Data are shown as mean±SEM, n=2.   
 
 
Quizartinib does not affect cardiac function but decreases CSP in healthy mice 
 
We treated wt mice with 10 mg/kg quizartinib for 28 days in a row. We observed no 
change in body weight and behaviour in both vehicle and quizartinib-treated mice. 
Echocardiography analysis revealed no significant differences between vehicle and 
quizartinib-treated mice regarding left ventricular dimensions and function (table3; 
n=24). However, ex vivo, quizartinib-treated mice showed an increased heart weight 
(6.02 ± 0.09 vs. 6.36 ± 0.1, p<0.05; n=12) (Fig.9), suggesting a subclinical 
hypertrophic response. Importantly, treatment of wt mice with quizartinib leads to a 
decrease of the CSP similar to the one observed in flk2-/- and flt3L-/- mice (2.36% ± 
0.32 vs. 1.98% ± 0.17, ns; n=6). This CSP depletion is again accentuated for the tip of 
the tail (0.07% ± 0.014  vs. 0.029% ± 0.06, p<0.05; n=6) (Fig.10). These data show 
that the flt3-inhibitor quizartinib affects the adult CSP progenitor pool in vivo.  
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Table 3: Hemodynamic values from 2D-echocardiography. Vehicle-treated vs. quizartinib-treated mice, 
n=24, data are shown as mean±SEM. One-way ANOVA, ns. LS: longitudinal strain. RS: radial strain: 
LVEF: left ventricular ejection fraction. LVEDD: left ventricular end-diastolic diameter. 
 
Fig.9: Comparison of ventricular weight/tibia length (VW/TL) ratio. Statistics: Vehicle-treated vs. 
quizartinib-treated mice, n=12, data are shown as mean±SEM. Unpaired t-test,  * p<0.05           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Fig.10: A. CMC- and erythrocyte-depleted population from digested hearts were stained with Hoechst 
and analysed by flow cytometry. Verapamil was used as negative control. Representative flow 
cytometry readouts of the CSP are shown. B. CSP% in the CMC- and erythrocyte-depleted population. 
Statistics: Vehicle-treated vs. quizartinib-treated mice, n=6, data are shown as mean±SEM. Mann 
Whitney test, ns.; C. Tip CSP % in the CMC- and erythrocyte-depleted population. Statistics: Vehicle-
treated vs. quizartinib-treated mice, n=6,, data are shown as mean±SEM. Mann Whitney test, *p<0.05. 
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SP-CPCs are enriched in quiescent cells 
 
Cellular quiescence is essential to prevent cellular damage and exhaustion of the 
proliferation capacity, and it is therefore pivotal for progenitor cell function in vivo.  
A quiescent state cannot be assessed by DNA-based cell cycle analysis since 
quiescent cells in G0 and active cells in G1 have the same amount of DNA and cannot 
be distinguished. To overcome this we used Pyronin Y (PY), which, similar as 
Hoechst, is a nucleic acid intercalant. When combined with Hoechst, PY is a 
molecule that binds only RNA (since Hoechst has a higher binding capacity for DNA) 
and through that cells in a quiescent state can be identified, since they have lower 
amounts of RNA (PY low-cells) compared to active cells (130). Compared to the 
main population (MP) the CSP is highly enriched in quiescent cells in G0 phase 
(Fig.11). We found that wt and flt3L-/- hearts have a similar percentage of quiescent 
cells in the CSP (68.97% ± 5.23 vs. 77.83% ± 6.78, ns; n=3) (Fig.12). 
 
 
 
 
 
 
Fig.11: Analysis of the Pyronin Y content of the main population and the CSP within the CMC- and 
erythrocyte-depleted population. Representative flow cytometry readouts of the total Hoechst-stained 
population are shown. 
 
 
 
 
 
 
 
Fig.12: Analysis of the percentage of Pyronin Y low cells in the CSP. n=3, data are shown as 
mean±SEM. Mann Whitney test, ns.           
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Freshly isolated flt3L-/- SP-CPCs have a reduced CD31- progenitor cell signature 
 
To compare the wt and flt3L-/- CSP cell transcriptomes, we purified RNA from 
freshly sorted SP-CPCs to avoid transcriptomic shifts deriving from the in vitro 
amplification. Prior to library preparation, RNA needed to be pre-amplified since SP-
CPCs reside in a quiescent state and are transcriptionally inactive, and therefore low 
in RNA content. 
29-35 millions reads were sequenced across samples (n=5), from which 19-28 
millions reads mapped to the genome. Transcripts were firstly filtered according to 
number per read per million or count per million (cpm). Only transcripts presenting at 
least 1cpm in at least 5 samples (indistinctly wt or flt3L-/-) were considered for gene 
expression analysis. Sample correlation and Principal Component Analysis (PCA) 
showed a high inter- and intra-sample variation. This high variability might be 
associated to several factors, including the heterogeneity of the CSP and the time and 
modality of isolation/sorting of these progenitors. 
Firstly we went through single gene comparison using a panel of genes, which 
characterized a CPC signature (69) (Table 4). Again we observed a high variability of 
expression of these transcripts between samples (data not shown) with no significant 
differences in expression between the two strains and no clustering of samples from 
the same strain (Fig.13). Specifically, we observed no detection of the most primitive 
stem cell transcripts POU domain, class 5, transcription factor 1 (Pouf51) and 
Nanog homeobox (Nanog), which are key genes for the maintenance of the 
pluripotency of stem cells. Instead, we observed high expression of the “less” 
primitive stemness markers kruppel-like factor (klf4), KIT proto-oncogene receptor 
tyrosine kinase (Kit) and lymphocyte antigen 6 complex, locus A (ly6a) (Table 4, 
flt3L-/- vs. wt, Log2A, pluripotency) confirming the progenitor signature of the CSP 
in vivo. Interestingly, between early and mature cardiac markers, the vascular markers 
showed the highest absolute expression, probably due to the high number of CD31+ 
cells (above 90%), i.e. endothelial progenitor cells, within the CSP (Table4, flt3L-/- 
vs. wt, Log2A, vascular).  
Single gene analysis also showed detection of flt3 receptor in both strains but with 
higher expression in the wt freshly isolated SP-CPCs (2.3 ± 0.30 vs. -0.1 ± 0.27, cpm 
as log2 expression, wt vs flt3L-/-, p<0.05, n=4-5). Surprisingly, although enhanced in 
the wt SP-CPCs, we also observed expression of the flt3L transcript in the KO CSP 
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progenitors (3.4 ± 0.30 vs. 1.75 ± 0.07, cpm as log2 expression, wt vs flt3L-/-, p<0.01, 
n=5). However, a careful analysis of the sequencing showed that the reads are 
uniquely mapping the truncated part of the flt3L and not the deleted part of the gene 
(Fig. 14), hence confirming knock-out of flt3L in flt3L-/- CSP.  
 
Setting a stringent false discovery rate (FDR) < 1e-6, we further proceeded with Gene 
Set Enrichment Analysis (GSEA), a computational comparison method based on 
defined sets of genes from MSigDB (version 5.2.) (131-133). Several curated gene 
sets were differentially regulated between wt and flt3L-/- RNA samples (Table 5). 
The gene set BOQUEST STEM CELL UP (223 genes) harbours the highest 
differentially expressed group of genes, with a false discovery rate (FDR) of 1.548e-
25 and an absLog2FC of 0.97 (flt3L-/- vs- wt). The BOQUEST STEM CELL UP 
gene set identifies a stromal stem cell transcriptome, in which the transcripts involved 
in cell cycle arrest, stem cell biology, and development of mesodermal and 
ectodermal organs were up-regulated in CD31- stromal stem cells harbouring a stem 
cell signature and differentiation plasticity (134). These transcripts are down-
regulated in freshly isolated flt3L-/- SP-CPCs suggesting a reduced CD31- progenitor 
cell signature. 
 
Table 4: Cardiac progenitor cell gene expression (69). Statistics: flt3L-/- vs. wt, n=5 (pool of 4 mice for 
each “n”). 
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Fig.13: Heat Map visualization and clustering of cardiac progenitor cell genes (gene panel from 
Noseda et al.(69)) after transcriptional comparison between freshly isolated wt and flt3L-/- SP-CPCs. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.14: Visualization of the sequencing reads mapping in the flt3L gene in wt and flt3L-/- RNA 
samples. The Flt3L gene in the KO-sample is truncated in the initial part due to homologous 
recombination during flt3L-/- mice generation (red square). 
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Table 5: Gene Set Enrichment Analysis of curated gene sets. Statistics: flt3L-/- vs. wt, n=5 (pool of 4 
mice for each “n”). Statistic filters: 1cmp in at least 5 samples (indistinctly wt or flt3L-/-);                        
adj.P.Val < 1e-6. 
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Freshly isolated SP-CPCs show multipotential properties 
 
As already investigated by several groups (5, 69, 105, 106), we assessed the 
multipotency of SP-CPCs with respect to the capacity to differentiate into the three 
major cardiac lineages, i.e., cardiomyocytes, vascular smooth muscle cells and 
endothelial cells.  
Freshly isolated SP-CPCs are quiescent and this facilitates the commitment towards a 
more differentiated phenotype. We observed expression of α-sarcomeric-actinin in 
Sca1+/CD31- SP-CPCs when co-cultured with NRVM for 3 weeks (Fig.15A). 
Freshly isolated SP-CPCs also expressed the endothelial marker vWF when cultured 
for 2-3 weeks in endothelial differentiation medium (Fig.15B).  
Of note, we found no differences in the percentage of vWF+ cells between wt and 
flt3L-/- SP-CPCs when freshly isolated and cultured in endothelial differentiation 
medium (9.69% ± 2.76 vs. 8.18% ± 2.58, ns; n=6) (data not shown).  
 
Fig.15: A. Sca1+/CD31- SP-CPCs were isolated from green-fluorescent protein (GFP) expressing mice 
and co-cultured with NRVM in DMEM 7%FCS medium for 3 weeks: SP-CPCs (green), α-sarcomeric-
actinin (red), dapi/nuclei (blue); B. Freshly isolated SP-CPCs in EGM-2 medium for 2-3 weeks: vWF 
(red), dapi/nuclei (blue). 
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Expanded SP-CPCs maintain a cardiac progenitor signature  
 
Sca1+/CD31- SP-CPCs are expandable in vitro, and this is the case for both wt and 
flt3L-/- SP-CPCs. Expanded wt and flt3L-/- SP-CPCs have a similar cardiac 
progenitor signature with respect to the expression of stem cell, early and late 
myogenic markers at the mRNA level (Fig.16A-B). 
Independently from culturing the cells in Medium1 or Medium2 (see material and 
methods), expanded wt and flt3L-/-  SP-CPCs maintained high positivity for the stem 
cell marker Sca1 and negativity for CD31 (76.95% ± 3.09 vs. 80.15% ± 3.19, ns; n=4 
in Medium1; 55.56% ± 2.54 vs. 61.65% ± 8.86, ns; n=5-6 in Medium2) (Fig.17-18).  
 
Two important features attributed (but not exclusive) to progenitor cells are the 
capacity to build clones and form spheres. We therefore assessed the capacity to 
generate cardiostem spheres and the clonogenicity of SP-CPCs. Expanded SP-CPCs 
from both strains were able to generate cardiostem spheres when cultured in 
bacteriological dishes (Fig.19A) and exhibited clonogenic capacity in the colony 
forming assay (Fig.14B). No significant differences were observed regarding the 
quantitiy of spheres or colonies between wt and flt3-/- SP-CPCs cultured over 2 
weeks (n=5-6) (Fig.19B).  
 
 
 
 
 
 
 
 
 
 
 
Fig.16: A. Gene expression of stemness and progenitor markers of  wt and flt3L-/- expanded SP-CPCs 
(P7). Embryonic stem cells (ESC) and whole heart homogenate (Heart) were used as positive and 
negative controls, respectively; B. Gene expression of cardiac transcription factors and cardiomyogenic 
markers of wt and flt3L-/- expanded SP-CPCs (P7). Whole heart homogenate and bone marrow (BM) 
were used as positive and negative controls, respectively. P7 = passage7 
Actn2: actinin alpha 2; Gapdh: glyceraldehyde-3-phosphate dehydrogenase; Gata4: GATA binding protein 4; 
Myh6: myosin, heavy chain 6, cardiac muscle, alpha; Nanog: Nanog homeobox; Nkx2.5: NK2 homeobox 5; 
Pou5f1: POU domain, class 5, transcription factor 1 (Oct-4); Tnni3: troponin I, cardiac 3. 
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Fig.17: Analysis of Sca1 and CD31 expression in SP-CPCs (P7) expanded in α-MEM 20%FCS 
medium. Representative FACS readouts of the expanded SP-CPCs are shown. Statistics: wt vs.     
flt3L-/-, n=4, data are shown as mean±SEM. Mann Whitney test, ns. P7 = passage7 
 
 
 
  
Fig.18: Analysis of Sca1 and CD31 expression in SP-CPCs (P7) expanded in stemness-preserving 
medium (Medium2). Representative FACS readouts of the expanded SP-CPCs are shown. Statistics: wt 
vs.    flt3L-/-, n=5-6, data are shown as mean±SEM. Mann Whitney test, ns. P7 = passage7 
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Fig.19: A. Cardiostem sphere formation assay in bacteriological dishes, 24h in medium without EGF 
and FGF supplement. B. Colony forming assay at 7, 10 and 14 days in stemness-preserving medium 
(Medium2). Representative experiment is shown. Statistics: wt vs. flt3L-/-, n=5-6, data are shown as 
mean±SEM. Mann Whitney test per each time point, ns.  
 
 
 
Flt3-intrinsic pathways are down-regulated in flt3L-/- SP-CPCs in culture 
 
We evaluated if lack of flt3L secretion in flt3L-/- SP-CPCs might affect flt3-related 
intracellular signalling pathways in culture. Using Medium1, which is not 
supplemented by additional growth factors, we observed a remarkable down-
regulation of main intracellular pathways implicated in flt3-dependent signaling such 
as Akt, Erk, Stat3 and Stat5, either through decreased phosphorylation or decrease of 
expression or both (Fig.20A), resulting in a markedly decreased phosphorylation ratio 
of Akt and – to a lesser extent – ERK. Interestingly, following siRNA-mediated 
knock-down of flt3L (si_flt3L) (Fig.20B) in wt SP-CPCs, we observed a similar 
down-regulation of flt3-related pathways to the one observed in flt3L-/- SP-CPCs. 
(Fig.20B). These data suggest that secretion of flt3L by SP-CPCs is important to 
preserve functional flt3 signaling over time in culture in the absence of additional or 
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compensatory growth factors.   
Surprisingly, we observed a different modulation of the flt3-related intracellular 
pathways in SP-CPCs cultured in medium supplemented with additional growth 
factors to preserve progenitor multipotency (Medium2) (Fig.21), in which case both 
phosphorylation and expression of signature signalling molecules was enhanced in the 
absence of intrinsic flt3-L, resulting in a maintained phosphorylation ratio. These data 
suggest that flt3L-signature signalling might be restored by compensatory factors 
supplemented to the medium, such as EGF and FGF, which share similar pathways.   
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Fig.20: A. Protein expression and phosphorylation of Akt, Erk, Stat3 and Stat5 in expanded wt and 
flt3L-/- SP-CPCs (P7) cultured in α-MEM 20%FCS medium (Medium1) as assessed by Western 
blotting. Representative blots are shown. Statistics wt vs flt3L-/-, n=3. data are shown as mean±SEM. 
Mann Whitney test, ns. ;B. Protein quantification of Akt, Stat3 and Stat5 (total and phosphorylated 
form) in SP-CPCs (P7) treated with scrambled siRNA- (si_Ctr) or flt3L-targeting siRNA- (si_flt3L-/-) 
in α-MEM 20%FCS medium (Medium1). Representative blots are shown. Statistics: si_Ctr vs. 
si_flt3L-/-, n=3, data are shown as mean±SEM. Mann Whitney test, ns. P7 = passage7.        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
wt flt3L-/- 
p-AktSer473 
GAPDH t-Akt 
60kd 
60kd 
37kd p-Erk 
GAPDH t-Erk 
42-44kd 
42-44kd 
37k
d p-Stat3Tyr705 t-Stat3 GAPDH 
90kd 
90kd 
37kd 
t-Stat5 GAPDH 90kd 37kd 
Thr202/Tyr204 
wt flt3L-/-
0.0
0.5
1.0
1.5
p-
A
kt
 / 
A
kt
wt flt3L-/-
0.0
0.5
1.0
1.5
2.0
2.5
A
kt
 / 
G
A
PD
H
wt flt3L-/-
0
1
2
3
p-
A
kt
 / 
G
A
PD
H
wt flt3L-/-
0.0
0.5
1.0
1.5
2.0
p-
Er
k 
/ G
A
PD
H
wt flt3L-/-
0.0
0.5
1.0
1.5
Er
k 
/ G
A
PD
H
wt flt3L-/-
0.0
0.5
1.0
1.5
p-
Er
k 
/ E
rk
** 
* 
 		 60	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.21:Protein quantification of Akt, Stat3 and Stat5 (total and phosphorylated form) in expanded wt 
and flt3L-/- SP-CPCs (P7) in medium supplemented with growth factors (Medium2). Representative 
blots are shown.  Statistics: wt vs. flt3L-/-, n=5-6, data are shown as mean±SEM. Mann Whitney test, 
*p<0.05, **p<0.01. P7 = passage7.        
         
 
 
In vitro characteristics of SP-CPCs from flt3L-deficient hearts  
 
In Medium1 expanded flt3L-/- SP-CPCs exhibited an accelerated proliferation rate 
over  time compared to wt SP-CPCs (3.5 fold at 5 days) (Fig.22). In addition,     
Flt3L-/- SP-CPCs showed enhanced Cyclin B1 expression 48h after G1-phase 
synchronization  (1.00 ± 0.21 vs. 3.64 ± 0.51, ns, n=3) (Fig.23A), suggesting faster 
G2/M phase transition of flt3L-/- compared to wt cells. In contrast, we observed no 
significant difference in Cyclin D1 expression (1.00 ± 0.17 vs. 1.24 ± 0.1, ns, n=3) 
(Fig.23B).  
Considering that differentiation and proliferation tend to follow distinct gene 
programs, differences in the proliferation rate may affect progenitor cell commitment 
and differentiation. Consistent with this hypothesis, we observed reduced mRNA 
expression of cardiomyogenic and endothelial lineage markers in flt3L-/- compared to 
wt SP-CPCs, and this difference was particularly pronounced for endothelial lineage 
genes (n=3) (Fig.24). 
These results, together with the loss of quiescent SP-CPCs in vivo, suggest that 
ablation of flt3L promotes untimely activation and proliferation of CPCs, hence 
jeopardizing their functionality.  
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Fig.22: SP-CPC count in α-MEM 20%FCS medium (Medium1) at days 3 and 5 in culture. Starting cell 
number = 1x104 . Statistics: wt vs. flt3L-/-, n=3, data are shown as mean±SEM. Mann Whitney test, ns. 
Fig.23: A-B: Protein expression of  cyclin B1 and D1 after 24 hours in α-MEM 20%FCS medium 
following synchronization in 0.1% FCS for 24 hours. Statistics: wt vs. flt3L-/-, n=3, data are shown as 
mean±SEM. Mann Whitney test, ns. 
Fig.24: Relative mRNA expression of cardiomyogenic and endothelial lineage genes in flt3L-/- SP-
CPCs compared to wt SP-CPCs in α-MEM 20%FCS medium. Statistics: flt3L-/- vs. wt, n=3, data are 
shown as mean±SEM, ns. P7 = passage7.        
Actn2: actinin alpha 2; Gata4: GATA binding protein 4; Myh6: myosin, heavy chain 6, cardiac muscle, alpha; 
Nkx2.5: NK2 homeobox 5; Tie2: TEK receptor tyrosine kinase; Tnni3: troponin I, cardiac 3; Vwf: von Willebrand 
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Expanded SP-CPCs preserve tri-lineage differentiation potential 
 
The potential future use of SP-CPCs for cardiac cell therapy requires preservation of a 
multi-lineage differentiation potential during ex vivo expansion. We observed that 
Medium1-based culturing favours the in vitro transformation of SP-CPCs 
(irrespective of their genotype, i.e. wt or flt3L-/-), which is characterized by a high 
proliferation rate and loss of their capability to differentiate into any of the three 
major cardiac lineages. In contrast, culturing of the cells in Medium2, with lower 
concentrations of serum and enriched with growth factors such as EGF and FGF, 
which have been shown to preserve “stemness” in other types of stem/progenitor cells 
such as adipose-derived mesenchymal stem cells and neural stem cells (135-137), 
abolished the difference in proliferation rate between wt and flt3L-/- SP-CPCs (n=4 
and 5) (Fig.25) while preserving the differentiation potential within expanded CSP 
cells of both genotypes.  
Using distinct differentiation protocols (Table 6), we could observe expression of 
markers of all three major cardiac lineages from the same Sca1+/CD31- CSP progeny. 
Consistent with observations made by other investigators in a different CPC type 
(Plaisance I et al., JACC Basic Transl Med 2016), we found a higher propensity of 
Sca1+/CD31- SP-CPCs to differentiate towards the smooth muscle cell lineage than 
towards endothelial or cardiomyogenic lineages. When cultured in PDGF-β-enriched 
medium (and in the absence of  EGF and FGF), SP-CPCs expressed mature 
filamentous structures of α-Smooth Muscle Actin (α-SMA) (Fig.26A).  
Through cardiostem sphere formation in EGF/FGF-deprived medium and using 
Laminin-precoated dishes we could induce the expression of the cardiomyogenic 
marker troponinI, which could be detected in the cytosol of a limited number of cells, 
but mostly without fibrillar organization (Fig.26B), with few exceptions (Fig.26C).  
To induce endothelial cell differentiation, we cultured CSP cells for two weeks in 
endothelial growth medium (EGM-2) using Fibronectin pre-coated dishes. In this 
context (although at low rate), expanded SP-CPCs expressed the endothelial marker 
vWF (Fig.27A). Additionally, they were able to form capillary-like structures in a 
tube formation assay within a matrigel scaffold (Fig.27B), supporting their 
endothelial potential.  
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Fig.25: SP-CPC count in stemness-preserving medium (Medium2) at days 3 and 5 in culture. Starting 
cell number = 1x104. Statistics: wt vs. flt3L-/-, n=4-5, data are shown as mean±SEM, ns. P7 = passage7.        
 
 
 
 Myogenic Smooth muscle Endothelial 
Expansion medium Medium2 Medium2 Medium2 
Sphere formation Yes (-EGF, -FGF) - - 
Coating Laminin - Fibronectin 
Serum starvation - 48h Medium2 0.1%FCS 48h Medium2 0.1%FCS 
Differentiation medium DMEM 7%FCS Medium2 (PDGF, -FGF, -EGF) EGM-2 
Culturing time 10-14 days 10-14 days 10-14 days 
 
Table 6: Cell differentiation protocols for cardiomyogenic, smooth muscle cell and endothelial lineages.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.26: Expanded Sca1+/CD31- SP-CPCs (P7) cultured for 10-14 days in A: smooth muscle 
differentiation medium,. Representative pictures are shown: α-SMA (red), dapi/nuclei (blue). 20X 
magnification; B-C: cardiomyogenic differentiation medium. Representative pictures are shown: 
troponinI (red), dapi/nuclei (blue). 20X magnification. P7 = passage7.        
α-SMA: α-Smooth Muscle Actin. 
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Fig.27: A. Expanded Sca1+/CD31- SP-CPCs (P7) cultured for 10-14 days in endothelial differentiation 
medium. Representative pictures are shown: vWF (red), dapi/nuclei (blue). 20X magnification; B. 
Expanded Sca1+/CD31- CSP cells after 24h in matrigel following 3 weeks of culturing in endothelial 
differentiation medium. BF, 2X magnification. P7 = passage7.        
vWF: von Willebrand factor 
 
Flt3L-/- CSP progenitor cells show a skewed proliferation - differentiation balance  
 
Once we defined the differentiation protocol for the three main cardiac lineages we 
compared the behaviour of wt and flt3L-/- SP-CPCs under differentiation conditions.  
With regard to smooth muscle cell differentiation, SP-CPCs from both genotpyes 
showed expression of mature structures of α-Smooth Muscle Actin (Fig.28A). 
However, whereas there was no difference with respect to the proliferation rate in 
Medium2 (Fig.25), but reminiscent of the proliferation behaviour in Medium1,   
flt3L-/- CSP cells proliferated much faster in smooth muscle differentiation medium 
as evidenced by the higher number of nuclei per field in flt3L-/- compared to wt 
cultures  (201 ± 65 vs. 320 ± 52, ns; n=4-6, 20X magnification) (Fig.28B). This 
resulted in a lower percentage of cells undergoing differentiation for this specific 
lineage (34.5% ± 9.4 vs. 14.9% ± 8.4, p=0.066; n=4-6) (Fig.28C).  
A similar observation was made when cells were cultured under cardiomyogenic 
differentiation conditions. Whereas SP-CPCs from both strains expressed troponinI 
(Fig.29A), flt3L-/- SP-CPCs also showed a high rate of proliferation (nuclei per field: 
45 ± 4 vs. 98 ± 10, p<0.01; n=5-4, 10X magnification) (Fig.29B) and this resulted in a 
lower percentage of troponinI-positive cells in flt3L-/- cultures compared to wt 
(62.8% ± 5.9 vs. 42% ± 8.2, p=0.063; n=4-5) (Fig.29C). Of note, we observed a 
particularly high percentage of troponinI-positive cells compared to previous works (5, 
103), which might be due to enrichment of the cardiomyogenic progenitor cell 
subfraction during cardiostem sphere formation.  
Endothelial vWF A	 B	 Endothelial 
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These data suggest that flt3L might act as a regulator of the 
proliferation/differentiation balance of SP-CPCs.  
 
 
Fig.28: A: Expanded Sca1+/CD31- SP-CPCs (P7) cultured for 10-14 days in smooth muscle 
differentiation medium. Representative pictures are shown: α-SMA (red), dapi/nuclei (blue). 20X 
magnification; B. Numbers of cells per field. Wt vs. flt3L-/-, n=4-5, data are shown as mean±SEM. 
Mann Whitney test, ns.; C. % of  α-SMA+ cells. Wt vs. flt3L-/-, n=4-6, data are shown as mean±SEM. 
Mann Whitney test, p=0.066. P7 = passage7.        
α-SMA: α-Smooth Muscle Actin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.29: A: Expanded Sca1+/CD31- SP-CPCs (P7) cultured for 10-14 days in cardiomyogenic 
differentiation medium. Representative pictures are shown: troponinI (red), dapi/nuclei (blue). 20X 
magnification; B. Numbers of cells per field. Wt vs. flt3L-/-, n=4-3, data are shown as mean±SEM. 
Mann Whitney test, **p<0.01; C. % of  α-SMA+ cells. Wt vs. flt3L-/-, n=5-4, data are shown as 
mean±SEM. Mann Whitney test, p=0.063. P7 = passage7.        
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Flt3L-/- CSP progenitor cells show no ability to organize in tube-like structures in 
matrigel upon endothelial differentiation 
 
The tube formation assay measures the ability of the cells, supported by the 
appropriate extracellular matrix and conditioned media, to form capillary-like 
structures (a.k.a tubes) (138). We evaluated the tube formation ability of expanded wt 
and flt3L-/- cells upon endothelial differentiation using a growth factor reduced 
matrigel. Following 24h in 0.1% FCS-supplement-free medium2 , SP-CPCs were 
cultured for 3 weeks in endothelial differentiation medium. Upon culturing in 
endothelial differentiation medium, we observed subtle differences in cell 
morphology between wt and flt3L-/- SP-CPCs, whereby wt cells sported mostly a 
spindle-like shape and signs of cell alignment, which were both absent in flt3L-/- cells 
(Fig.30). Cells were then trypsinized and identical cell numbers were transferred on 
matrigel for additional 24h. Wt SP-CPCs were able to organize in capillary-like 
structures (Fig.31A), and this ability was completely absent in flt3L-/- cells (Fig.31B). 
These data show that flt3L-/- cells fail to differentiate into mature endothelial cells 
under appropriate differentiation conditions.  
 
 
 
 
 
 
 
 
 
 
Fig.30: Expanded Sca1+/CD31- SP-CPCs (P7) cultured for 3 weeks in endothelial differentiation 
medium. Representative pictures are shown: BF, 4X magnification. P7 = passage7.       
 
 
 
 
 
 
 
 
 
 
 
 
Fig.31: A-B. Expanded wt and flt3L-/- Sca1+/CD31- SP-CPCs (P7) after 24h in factor reduced-
matrigel following 3 weeks in endothelial differentiation medium. Representative pictures are shown: 
BF, 2X magnification. P7 = passage7.        
flt3L-/- wt 
flt3L-/- wt 
A	 B	
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Chapter 2. Flt3 signaling in the healthy and injured heart 
 
 
Flt3L-/- mice exhibit impaired cardiac function 
 
Given that flt3 signaling appears important for cardiac progenitor cell maintenance 
and function, and that flt3L deficiency causes a disturbance of the adult cardiac 
progenitor cell homeostasis in vivo, we sought to test whether absence of functional 
flt3 signaling affects adult cardiac structure and function. Conventional 
echocardiography on age-matched 12 week-old wt and flt3L-/- mice showed a 
moderate but significant decrease in global systolic function in flt3L-/- mice as 
assessed by left ventricular (LV) ejection fraction (LVEF, 50.6% ± 1.7 vs. 43.3% ± 
1.8, p<0.01; n=16-18, Fig.32A), whereas cardiac structure in terms of wall 
thicknesses and left ventricular (LV) diameters was virtually maintained (LV end-
diastolic diameter: 4.50mm ± 0.07 vs. 4.36mm ± 0.06, ns; n=16-18) (Fig.32B). Using 
speckle-tracking echocardiography (139) we further evaluated deformation 
parameters of the myocardium in the long axis as longitudinal strain (LS) and radial 
strain (RS), which assess contraction strength of the myocardium and are considered 
early predictors of (subclinical) functional decline. As for conventional parameters, 
flt3L-/- mice showed reduced LS (-9.8Pk% ± 0.5 vs. -8.1Pk% ± 0.4, p<0.05; n=16-
18) and RS values (20.8Pk% ± 1.0 vs. 17.5Pk% ± 1.2, p<0.05; n=16-18) (Fig.32C-D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.32: Echocardiographic measurements in 12 weeks-old mice of A. left ventricular ejection fraction 
(LVEF); B. left ventricular end-diastolic diameter (LVEDD); C. longitudinal strain (LS); D. radial 
strain (RS). Statistics: wt vs. flt3L-/-, n=16-18, data are shown as mean±SEM. Mann Whitney test for 
LVEF, unpaired t-test for LVEED,LS and RS, *p<0.05, **p<0.01.  
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Flt3L-/- mice have smaller hearts and smaller CMC size 
 
Wt and flt3L-/- mice showed no significant difference with regard to body weight 
(29.1g ± 0.4 vs. 27.4g ± 0.4, p<0.05; n=12) (Fig.33A). In contrast, flt3L-/- mice had a 
reduced LV weight to tibia length ratio (6.96 ± 0.45 vs. 5.96 ± 0.16, p=0.088; n=6-8) 
(Fig.33B) and reduced CMC size according to the cross-sectional area (249.9µm2 ± 
13.5 vs. 213.8µm2 ± 11.17, p=0.053; n=9-10), as assessed by wheat germ agglutinin 
(WGA) staining of cellular membranes (Fig.34). Of note, flt3L-/- mice had LV 
dysfunction and this might induce lung congestion. Surprisingly, we observed no 
accumulation of liquids in the flt3L-/- lungs, but instead the wet to dry lung weight 
ratio was reduced compared to wt mice (4.25 ± 0.06 vs. 4.09 ± 0.04, p=0.073; n=6-8) 
(Fig.35).  
    
Fig.33: A. Measurement of 12 weeks-old mice body weight. Statistics: wt vs. flt3L-/-, n=12, data are 
shown as mean±SEM. Unpaired t-test, ns.; B. Measurement of the heart weight as ventricular 
weight/tibia length ratio (VW/TL). Statistics: wt vs. flt3L-/-, n=6-8, data are shown as mean±SEM. 
Mann Whitney test, p=0.08. 
 
 
Fig.34: Analysis of the cross-sectional area of the CMCs in the free LV wall. Representative pictures 
are shown: WGA lectin (green), dapi/nuclei (blue). Statistics: wt vs. flt3L-/-, n=9-10, data are shown as 
mean±SEM. Unpaired t-test, p=0.053. 
WGA: Wheat Germ Agglutinin 
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Fig.35: Analysis of the lung wet/dry ratio. Statistics: wt vs. flt3L-/-, n=6-8, data are shown as 
mean±SEM. Mann Whitney test, p=0.073. 
 
 
Flt3L-/- mice show reduced capillary density  
 
The smaller CMC size and the decreased cardiac function in the absence of cardiac 
injury suggest a developmental pathology in flt3L-/- mice. Given the reduced wet to 
dry lung ratio, which suggests lower perfusion and/or vascularization of the lungs of 
flt3L-/- mice, as well as the decreased capacity of flt3L-deficient SP-CPCs for 
endothelial differentiation and maturation, we primarily focused on myocardial 
vascularization, assessing the numbers of large and middle-sized vessels as well as the 
capillary density in the LV. We firstly analysed the cardiac vasculature using von 
Willebrand factor (vWF), a marker of mature endothelial cells. We found a 
moderately and non-significantly decreased number of medium to large-sized vessels 
(diameter > 20µm) in flt3L-/- compared to wt hearts (9.05 ± 0.88 vs. 6.39 ± 1.21, 
p=0.09; n=10) (Fig.36). To further analyse microvasculature in the heart, we used 
isolectin IB4, which  recognises polysaccharides present in all endothelial cells (140). 
We observed a significantly reduced number of capillaries per myocyte in flt3L-/- 
mice (1.36 ± 0.07 vs. 1.14 ± 0.05, p<0.05; n=9-10) (Fig.37), suggesting a rarefaction 
of the microvascular bed. In contrast, we did not observe any microinjuries in terms 
of enhanced apoptosis or fibrosis in flt3L-/- hearts. Specifically, there was no 
difference in the number of TUNEL-positive nuclei (apoptotic nuclei) between     
flt3L-/- and wt hearts (0.53 ± 0.04 vs. 0.46 ± 0.03, ns; n=5) (Fig.38A) and no increase 
in fibrosis could be detected (Fig.38B). These data suggest microvascular rarefaction 
leading to malnutrition and decreased CMC size associated with subclinical systolic 
dysfunction of the flt3L-/- hearts.  
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Fig.36: Analysis of  the middle- to large-sized vessel density in the LV. Representative pictures are 
shown: vWF (red), dapi/nuclei (blue). Statistics: wt vs. flt3L-/-, n=10, data are shown as mean±SEM. 
Unpaired t-test, p=0.09.  
vWF: von Willebrand factor 
 
 
Fig.37: Analysis of  the capillary density in the LV. Representative pictures are shown: IB4 (red), 
WGA (green). Statistics: wt vs. flt3L-/-, n=9-10, data are shown as mean±SEM. Unpaired t-test, 
*p<0.05. 
WGA: Wheat Germ Agglutinin; IB4: isolectin B4 
 
Fig.38: A. Detection and quantification of apoptotic CMCs via TUNEL staining. Statistics: wt vs. 
flt3L-/-, n=5, data are shown as mean±SEM. Mann Whitney test, ns.; B. Detection of fibrotic tissue via 
Masson’s Trichrome staining. Representative pictures are shown: muscle tissue (red), collagen/fibrosis 
(blue). Infarcted heart was used a positive control. 
TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling 
 
 
 
 
 
 
 
wt flt3L-/-
0.0
0.5
1.0
1.5
2.0
C
ap
ill
ar
ie
s 
/ m
yo
cy
te
s
wt flt3L-/-
0
5
10
15
Ve
ss
el
s 
(∅
>
20
µ
m
2 )
  /
 m
m
2 
wt p=0.09 flt3L-/- 
vWF 
* 
wt flt3L-/-
0.0
0.2
0.4
0.6
0.8
1.0
TU
N
EL
-p
os
iti
ve
 n
uc
le
i /
 m
m
2
A	 B	
WGA	+	IB4 
																	Positive	ctrl.	 													wt																														flt3L-/-		 
	(infarcted	heart) 
flt3L-/- wt 
 		 71	
Flt3L ablation is protective during post-MI cardiac remodelling   
 
Flt3/flt3L is a cytoprotective system in the ischemically injured heart (3) and flt3L 
ablation is associated with disturbed cardiac progenitor cell homeostasis and function, 
microvascular rarefaction and subclinical cardiac dysfunction. In this context, we 
assessed the implications of flt3L-deficiency in the acute and post-acute phase after 
myocardial infarction (MI). We induced MI by LAD ligation (see methods) and 
followed-up on the mice clinically and echocardiographically over 7 days. We 
observed no difference in post-MI survival between the two strains (Fig.39). LV 
weight to tibia length ratio significantly increased after MI with no difference 
between the two strains (7.97 ± 0.55 vs. 7.64 ± 0.57, ns; n=8,10) (Fig.40). LVEF was 
significantly decreased in wt mice after MI compared to sham (43.35% ± 4.86  vs. 
15.34% ± 1.78, p<0.05; n=6,8). Surprisingly, however, LVEF was less compromised 
in flt3L-/- mice, which showed only a non-significant decline in LVEF after MI 
compared to sham (43.32% ± 2.13  vs. 30.69% ± 5.32, ns; n=8-10) and to wt-MI mice 
(30.69% ± 5.32  vs. 15.34% ± 1.78, ns; n=8-10). (Fig.41A). Consistently, wt mice 
showed higher post-MI LV dilation as assessed by LVEDD compared to the flt3L-/- 
group (5.74mm ± 0.32  vs. 4.69mm ± 0.18, p<0.01; n=8-10) (Fig,41B). Deformation 
parameters supported a protective role of flt3L-/- during the early phase of 
remodelling as LS (4.07% ± 0.56  vs. 6.28% ± 0.75, ns; n=8-10) and – more 
pronounced – RS (7.92% ± 1.05  vs. 13.46% ± 2.41, ns; n=8-10) were higher in  
flt3L-/- mice compared to wt at 1 week after MI (Fig.41C-D). 
 
 
 
 
 
 
 
Fig.39: Post-MI percent survival over 7 days post-surgery in wt-infarcted (wt_MI), flt3L-/- infarcted 
(flt3L-/-_MI) and sham (wt+flt3L-/-_sham)  mice. Statistics: wt_MI, flt3L-/-_MI, wt+flt3L-/-_sham, 
n=8, 10, 14, survival comparison test, ns. 
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Fig.40: Ventricular weight to tibia length ratio (VW/TL). Statistics: wt sham (wt_sham), wt-infarcted 
(wt_MI), flt3L-/- sham (flt3L-/-_sham) flt3L-/- infarcted (flt3L-/-_MI) mice, n=6-8-8-10 data are 
shown as mean±SEM. 2way ANOVA, *p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.41: Echo-measurements in 9 week-old mice, 1 week after permanent occlusion of the left anterior 
descending coronary artery. A. left ventricular ejection fraction (LVEF); B. left ventricular end-
diastolic diameter (LVEDD); C. longitudinal strain (LS); D. radial strain (RS). Statistics on wt sham 
(wt_sham), wt-infarcted (wt_MI), flt3L-/- sham (flt3L-/-_sham) flt3L-/- infarcted (flt3L-/-_MI) mice, 
n=6-8-8-10 data are shown as mean±SEM. 2way ANOVA, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
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Flt3L-/- hearts appear to have an intrinsically enhanced inflammatory response 
 
We compared the wt and flt3L-/- cardiac transcriptome using RNA isolated from 
whole heart homogenates. 60 to 70 millions reads were sequenced across samples 
(n=4), from which 27-32 millions reads mapped to the genome. As for CSP 
transcriptome analysis, only transcripts presenting at least 1cpm in at least 4 samples 
(indistinctly wt or flt3L-/-) were considered for gene expression analysis. In contrast 
to CSP cell samples, samples from wt and flt3L-/- whole hearts showed a remarkably 
high correlation within the group (0.987 and 0.986, respectively) and the PCA 
describing 55.05% of the observed differential expression between the samples is 
correlated with the KO of the flt3L gene.  
As in the previous trascriptome analysis, flt3L transcript is detected in both strains but 
again only as truncated gene in the flt3L-/- hearts. Flt3 receptor is detected only by 
few reads.  
Performing GSEA using a FDR < 1e-6, we focused on the Gene Ontology (GO) gene 
sets, in which genes are assigned to a set of predefined bins depending on their 
functional characteristics. Several GO gene sets were differentially regulated between 
wt and flt3L-/- (Table 5). The differential expression of these gene sets occurred in 
both direction (up-regulation or down-regulation) but the most differentially regulated 
GO gene sets were up-regulated in the flt3L-/- hearts. In particular, we found a 
profound up-regulation of gene sets involved in the inflammatory response and in 
immune cell migration (Table 7). These novel transcriptional findings suggest that 
flt3L-/- hearts have an intrinsically enhanced inflammatory response, which might be 
protective during the acute phase of the post-MI remodelling and might explain the 
partial preservation of LV function in flt3L-/- mice after MI (Fig.41). 
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Table 7: Gene Set Enrichment Analysis of Gene Ontology gene sets. Statistics: flt3L-/- vs wt, n=4. 
Statistics filters: 1: 1cmp in at least 4 samples (indistinctly wt or flt3L-/-); 2: adj.P.Val < 1e-6. 
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Discussion  
 
Taken together, this thesis work contributes to an improved understanding of CPC 
biology and of the role of Flt3L, an early acting hematopoietic cytokine, in the heart. 
Firstly, we show that a tight control of CPC ex vivo expansion conditions together 
with the use of specific growth factors, i. e. EGF and FGF, are pivotal to maintain the 
CPC phenotype and differentiation potential, which may contribute to a better 
performance of such cells in the scope of regenerative cell therapy. Secondly, we 
uncover a so far unrecognized role of flt3/flt3L in the regulation of the adult cardiac 
progenitor pool. Specifically, we show that flt3L contributes to the maintenance of the 
CPC signature and the functionality of CPCs via a mechanism that includes the 
balancing of their proliferation and differentiation, pointing towards potentially 
important parallels between CPC and hematopoietic progenitor cell biology. Finally, 
we show that whereas non-conditional knock-out of Flt3L leads to reduced 
myocardial vascularization and subtle cardiac dysfunction, flt3L deficiency appears 
actually protective in the post-acute phase after myocardial infarction. In the 
following paragraphs, these three key observations of my thesis will be further 
discussed.   
 
For the past decade, cell therapy has emerged as an appealing novel approach to 
regenerate lost cardiac tissue after major injury such as myocardial infarction. 
However, so far, proof of clinical benefit in large-scale randomized and double-
blinded clinical trials is still missing. Current research is focusing on the many aspects 
of potential cell therapy that are still not understood and that include the search for the 
ideal cell type. Several endogenous precursors have been investigated in pre-clinical 
and clinical studies showing regenerative potential and functional improvement of the 
heart (141, 142). Still, survival and differentiation efficiency of transplanted cells 
remain poor.  
An ideal cell type for replacing damaged myocardial tissue would have the ability to 
survive, integrate into an ischemic area, and stimulate endogenous regeneration via 
lineages-differentiation to support the pre-existing myocardium. So far different cell 
types have been explored in these regards. Several clinical trials using primitive cell 
population from heart or BM have shown safe delivery and functional improvement 
of cardiac output when administered to ischemic patients (75, 76, 143), but so far 
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none have met the ideal expectations.  
Issues associated to cell therapy are multiple. Cell survival after transplantation is low 
regardless of the cell type and the injury model (144). Similarly, injected cells in 
murine MI-models have shown poor retention capacity: cell retention at day 1 varied 
from 1 to 8%, declining to 0.1–0.5% at 2 weeks (69). Several tissue engineering 
approaches such as the implantation of cell sheets, epicardial patches, or delivery in 
biomaterials have been described to increase the engraftment rate (145-147).  
A second issue is defining the right timing of delivery of ex vivo expanded CPCs. The 
optimal maturation state of CMCs for transplantation is not fully understood yet. 
Mature adult CMCs do not survive transplantation and immature CMCs have slow 
conduction and may be cause of arrhythmias (148).   
A last consideration points out that, despite the capability of these cells to migrate in 
the ischemic area and differentiate, only a small portion of engrafted cells express 
myogenic or vascular proteins and most of them lack complete maturation (69, 106). 
This partial loss of the multilineage differentiation potential might occur during the 
ex-vivo amplification, throughout which maintenance of CPC properties remains an 
obligatory step in order to use these progenitors for cell therapy.  
Several factors might affect CPC properties during cell expansion. These could be 
stress factors such as the isolation procedure and the switch from a 3-dimensional to a 
2-dimensional environment. But mainly the lack of signals such as paracrine factors 
or cell-cell contacts, which typically occur in the niche environment and are important 
for CPC quiescence and function, may affect ex vivo CPC behavior. All these factors 
might be responsible for a partial loss of differentiation efficiency during cell 
expansion and a consequent lack of complete maturation in vitro or in vivo when 
transplanted in the heart. 
Different populations of CPCs have been identified in the heart, according to unique 
cell surface marker patterns. To investigate this final point we isolated a specific type 
of CPCs based on their ability to efficiently efflux Hoechst dye, knows as the CSP, 
which, as other candidate cells, has been well described in several animal models 
(149), and also in the adult human heart (150).  
We showed that careful adjustments of culture conditions are necessary to preserve 
the multipotential properties of SP-CPCs expanded in vitro. In particular, SP-CPCs 
expressed specific lineage markers and preserved their differentiation potential, when 
expanded in low-serum conditions and in the presence of EGF and FGF, which are 
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commonly added into stem cell cultures to enhance their proliferation capacity while 
preserving their multipotency, a process also known as self-renewing proliferation 
(135-137).   
 
Flt3/flt3L is an important regulator of hematopoietic progenitor cells, mainly 
controlling their proliferation and differentiation. Although its role is well known in 
the BM (26, 31, 33), it has also been implicated in the regulation of progenitor cell 
function from other organs, including neural and muscle-derived stem cells  (54, 55, 
123). In this context, we wanted to evaluate if and how flt3 signaling affects the adult 
progenitor cell pool in the heart.  
Our in vivo findings suggest an untimely activation of a proportion of physiologically 
quiescent progenitor cells in flt3L-/- mice, prompting them to leave their quiescent 
state and, hence, the SP phenotype. In line with this finding, GSEA unveiled a 
reduced CD31- progenitor cell signature in flt3L-/- SP-CPCs, with downregulation of 
transcripts involved in cell cycle arrest and stemness. 
Sorted wt and flt3L-/- Sca1+/CD31- SP-CPCs are expandable in vitro. In EGF/FGF-
deprived medium, flt3L-/- SP-CPCs showed a hyperproliferative state compared to wt 
cells and lower expression of lineage markers. Considering that proliferation and 
differentiation tend to follow opposite pathways, these data point towards a lower 
differentiation efficiency of flt3L-/- SP-CPCs. Nevertheless, when pushed towards 
specific cardiac lineages with differentiation media, SP-CPCs of both genotypes (wt 
and flt3L-/-) failed to express lineage markers, suggesting that this expansion medium 
favours an in vitro transformation characterized by a high proliferation rate, in which 
SP-CPCs fail to exit the cell cycle and undergo differentiation.  
In contrast, low serum and EGF/FGF-enriched medium abolished the phenotypic 
difference between wt and flt3L-/- SP-CPCs in terms of proliferation and helped 
preserve a primitive cellular state, which made CSP progenitors more prone to cell 
differentiation. However, differentiation media destabilized this state and unmasked 
strain differences with respect to proliferation and differentiation. Expanded 
Sca1+/CD31- flt3L-/- SP-CPCs showed a higher proliferation rate when cultured in 
differentiation media (irrespective of the targeted lineage and – hence – the 
composition of the medium). This increased cycling of flt3L-/- cells might negatively 
affect the commitment and differentiation capacity of a proportion of flt3L-/- SP-
CPCs, which is reflected by a lower percentage of CPCs expressing smooth muscle 
 		 78	
and cardiomyogenic proteins.  
Differently from these two lineages, and although freshly isolated SP-CPCs showed 
between 10-15% of positivity for vWF (detected in cytoplasmatic vacuoles) (Fig.9B), 
we observed particularly low rates of vWF+ cells within expanded SP-CPCs when 
cultured in endothelial differentiation medium (Fig.24A). There are two possible 
explanations for the poor efficiency to differentiate towards the endothelial lineage: 
one is related to the fact that the highest capacity for endothelial differentiation is 
mainly linked to the CD31-positive fraction of Sca1+ SP-CPCs (105), while instead 
in our study expanded CD31-negative SP-CPCs were used. The second explanation 
may relate to technical issues (e.g. staining efficiency), which are currently still under 
investigation in the laboratory. Although expanded SP-CPCs exhibited low 
expression of mature endothelial markers, differentiated SP-CPCs from wt mice were 
able to organize in capillary-like structures in response to angiogenic factors (138). 
After 3 weeks of culturing in endothelial differentiation medium, wt SP-CPCs formed 
endothelial tube-like structures in matrigel, indicating successful endothelial 
differentiation despite low expression of vWF and favouring technical limitations for 
the low rate of vWF positivity after the differentiation procedure. In contrast, using an 
identical differentiation protocol, flt3L-/- SP-CPCs showed no ability to organize in 
capillary-like structures when cultured in matrigel upon three weeks in endothelial 
differentiation medium.  
These data suggest that flt3-signaling is mandatory for the maintenance of a 
molecular signature that is required for adult cardiac progenitor cell quiescence and 
functionality, and propose flt3 as a so far unrecognized regulator of the adult cardiac 
progenitor pool. These findings are in part reminiscent of a recently uncovered role of 
Flt3 signaling in skeletal muscle precursors (54, 55). In both cell types flt3L appears 
important to balance proliferation and myogenic differentiation. Lack of functional 
flt3 signaling leads to increased proliferation and limited differentiation efficiency. 
These data suggest that flt3 signaling might be important for the coordinated 
repression of proliferation in favour of cell cycle exit, which is pivotal for promoting 
differentiation. In this regard, the role of flt3 signaling in myogenic progenitor and 
precursor cells shows both similarities and differences with respect to its role in the 
hematopoietic progenitor cell pool. Whereas the role of flt3 in the heart is consistent 
with the reported instructive role of flt3L in early lineage commitment of 
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lymphoid/myeloid progenitors (33), it diverges from the described pro-proliferative 
role of flt3L in lymphoid progenitors (28, 29, 38). 
 
Flt3/flt3L is a cytoprotective system in the heart and exogenous delivery of 
recombinant flt3L directly into the myocardium ameliorates post-MI function (3). In 
this context, we investigated how flt3L ablation affects structure and function of the 
healthy and injured heart. 
Non-conditional ablation of flt3L causes subclinical LV systolic dysfunction in flt3L-
/- mice, although we observed no differences with regard to cardiac structure and 
dimensions as assessed echocardiographically. Ex vivo, however, Flt3L-/- hearts are 
lower in relative weight and exhibit reduced CMC size. In addition, Flt3L-/- mice 
show a rarefaction of the microvascular bed in the absence of detectable micro-
injuries. Taken together, we hypothesize that the observed phenotype might be the 
result of a nutritional or supply problem, possibly originating in disturbed 
(micro)vasculogenesis already during the early stages of cardiac development.  
Heart microvascularization is the result of complex angiogenic and vasculogenic 
processes occurring during heart development (151, 152). The healthy endothelium is 
turned-over approximately every three years (153). Renewal of the vascular cells in 
the adult heart does not occur exclusively by angiogenesis, circulating endothelial 
progenitor cells (154) or resident CPCs (66) represent at least two sources of vascular 
progenitors that actively contribute to new vessel growth.  
In this work, we showed that CSP cells have the potential to commit towards the 
endothelial lineage and form capillary-like structures in matrigel, and this potential is 
clearly lost in expanded flt3L-/- cells. Although SP-CPCs do not represent the only 
type of progenitor cells with endothelial potential residing in the heart (66, 78, 104, 
105, 107), the failure of flt3L-/- SP-CPCs to efficiently differentiate into endothelial 
cells might be one of the causes of the reduced number of capillaries per myocyte 
observed in flt3L-/- mice. However, it might be notable that other TK receptors, such 
as VEGF and Tie receptors, have been well described to directly mediate 
angiogenesis (155). Therefore, we cannot exclude a so far undiscovered role of flt3 
signaling in the angiogenic processes during cardiac development or post-natal 
growth and homeostasis. 
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These findings demonstrate that, although these mice are viable with no previously 
described cardiac phenotype, ablation of flt3 signaling has an impact on cardiac organ 
and progenitor cell homeostasis.  
As mentioned, intramyocardial activation of flt3 via exogenous flt3L is protective 
against adverse cardiac remodelling after MI (3) and flt3L ablation (via CPCs?) is 
responsible for a rarefaction of the microvascular bed in the ventricular wall. In this 
context, we assessed the implications of a lack of a functional flt3 system in the 
ischemically injured heart, in which cell survival and neovascularization are important 
features of cardiac tissue preservation and repair, hypothesizing that both of these 
features are impaired in flt3L-deficient hearts, hence leading to worse post-infarct 
remodelling and outcome.  
Contrary to our hypothesis, however, we observed that flt3L ablation is protective 
rather than deleterious during the acute and post-acute phase after MI. In particular, 
both the reduction in LV pump function as well as LV dilation were both markedly 
mitigated in infarcted flt3L-/- compared to wt hearts. Whereas these findings suggest 
that additional mechanisms as discussed below are responsible for the beneficial 
effects in the early post-infarct phase, they do not exclude potential deleterious effects 
of flt3L ablation during the later, chronic phase of post-MI remodelling, when the 
inflammatory response subsides and function-preserving and regenerative processes 
are taking the lead (108, 112). 
Flt3 signaling has a major role in normal haematopoiesis and it modulates immune 
cell homeostasis and function (1). The inflammatory response and the leucocyte 
chemotaxis at the injury site are major events during the acute phase of the post-MI 
remodelling. Their injury-mediated activation is pivotal to contain the ischemic 
damage and trigger an immediate repair process to retain cardiac function despite the 
newly-formed necrotic tissue (108, 112, 113). In this context we currently 
hypothesize that the protective effect observed in the flt3L-/- mice after 1 week post-
MI (Fig.40) might be associated to a modulation of the inflammatory response, which 
occurs early in the repair process. Our hypothesis is supported by the transcriptome 
analysis of the heart tissue from wt and flt3L-/- mice, which revealed an endogenous 
up-regulation of genes involved in the inflammatory response and cell migration in 
the flt3L-/- hearts. These findings suggest that these mice might initiate a stronger and 
quicker inflammatory response following injury and that this appears to be consistent 
with the more favourable post-infarct cardiac function.  
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Anthracyclines are an important class of drugs in the treatment of cancer, but remain  
problematic chemotherapeutic agents given their cardiotoxic effects (10, 156, 157). 
Induction of cardiomyopathy and congestive heart failure (CHF) has stressed the need 
for proper prevention and alternative treatment strategies, as targeted cancer therapies 
including TKIs. As to date, little is known about the occurrence, timing and potential 
severity of TKI-related cardiac side effects (12).  
Multi-kinase inhibitors, i. e. sunitinib and sorafenib target several kinase receptors, 
including flt3 (158, 159); they have shown efficacy in metastatic renal cell carcinoma 
and gastrointestinal stromal tumours but TKI-associated cardiotoxicity was reported 
in approximately 10% of the patients (43).  In particular, aside inducing myocyte 
necrotic death, sorafenib significantly reduced the survival of mice undergoing MI 
after 1 week of treatment (44). 
Second generation inhibitors, i. e. quizartinib (AC220), represent the state-of-the-art 
design for their high flt3-binding specificity, favouring a more targeted therapy and 
supposedly limiting off-target cardiotoxicity. In a phase II study, enrolling patients 
who were refractory to first-line chemotherapy or relapsed after hematopoietic stem 
cell transplantation (HSCT), quizartinib caused only transient QTc prolongation 
(13%) (47) and so far no late onset toxicity has been described. Still a profound gap of 
knowledge exists as to whether these new generation inhibitors targeting flt3 have 
cardiac side effects or not. 
In our study, 4-weeks quizartinib treatment did not alter cardiac performance, but 
induced an increase in left ventricular dimensions, suggesting a subclinical 
hypertrophic response. 
Cancer therapy may also negatively affect CPC function. In particular, administration 
of DOXO in rats leads to dilated cardiomyopathy with irreversible growth arrest and 
cellular senescence of CPCs (72). In a mouse model prone to developing heart failure 
as a result of anticancer therapies targeting Stat3 or DOXO (78), CPCs have a reduced 
endothelial differentiation capacity. These data suggest that an impairment of the CPC 
functionality might contribute to cancer therapy-induced cardiomyopathy and this 
could be the case for traditional chemotherapy (DOXO) as well as for targeted 
therapies (e.g., TKIs). Consistent with such hypothesis, in our in vivo study, 28 day-
treatment with quizartinib caused a disturbance of the CPC homeostasis similar to the 
one observed in flt3L-/- SP-CPCs, suggesting that targeted (flt3-targeted in our case) 
short-term treatment may indeed cause potential cardiac side effects on the cellular 
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level, which may become relevant when co-inciding with an ischemic event 
(respective studies are currently ongoing in the lab). 
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Conclusions 
 
In a context of a potential prospective use of CPCs in cardiac cell therapy, we show 
that careful adjustments of culturing conditions are pivotal to preserve progenitor 
potential, and thus the capability for multi-lineage commitment and differentiation, 
during ex vivo expansion.  
With respect to its main focus, this work supports a novel role of flt3 signaling in the 
regulation of progenitor cells in the heart. Specifically, we show that flt3 contributes 
to the maintenance of a quiescent and functional cardiac progenitor cell pool in vivo. 
Flt3 is important for CPC lineage commitment and differentiation by regulating the 
balance between proliferation and differentiation in favour of differentiation. These 
findings reveal parallels between the roles of flt3 in the regulation of cardiac and the 
instructive role described in hematopoietic progenitor cells, and thus provide 
important novel insights into CPC biology. They also raise the possibility of a tighter 
relationship between cardiac and hematopoietic progenitor cells than previously 
thought that warrants further investigation. 
We also found that flt3 contributes to the myocardial microvasculature, it is during 
development or postnatal growth and homeostasis. Although this could possibly be 
linked to the impaired endothelial differentiation potential of CPCs in the absence of 
flt3, additional mechanisms, including such related to angiogenesis rather than 
vasculogenesis may apply. Surprisingly, lack of endogenous flt3L was protective 
during the early, post-acute phase after myocardial infarction, as it mitigated the 
decline in cardiac function and ventricular dilation. With preliminary data pointing 
towards a potential modulation of the post-infarct inflammatory response 
investigation of the underling mechanism is currently ongoing in the laboratory.  
This work was initiated against the background of cancer drug cardiotoxicity, as seen 
more and more often given the remarkable increase in lifespan through modern-day 
cancer therapies including receptor TKs. Better knowledge of the roles of cancer drug 
targets in the heart will help anticipate cardiac side effects, thus enabling early 
monitoring and interdisciplinary management of cancer patients. Our findings 
uncover so far unknown functions of flt3 in the heart, which are important in such  
context. 
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Future Perspective 
 
As knowledge of CPC biology and their regulation is still limited, it will be important 
to understand the precise mechanisms through which flt3 regulates the balance 
between CPC proliferation and differentiation. Such findings will shed new light on 
how proliferation and differentiation are coordinated, and – hence – how 
differentiation is initiated, in CPCs. As previously shown for skeletal myoblasts, flt3 
signaling is important for cell cycle exit and cell commitment towards a more 
differentiated phenotype (54) In our study, wt and flt3L-/- CPCs show a similar 
behaviour (in terms of proliferation) when expanded in stemness-preserving medium, 
suggesting that growth factors supplemented to the medium compensate for the lack 
of flt3L, thus maintaining the signalling signature necessary for keeping the cells in 
steady-state. Instead multiple types of differentiation media, irrespective of the 
targeted lineage, unmask strain differences and cause a striking increase of the 
proliferation rate in flt3L-/- cells, with consequently reduced differentiation efficiency 
(Fig.28-29). Although we used progenitor potential-preserving culturing conditions 
for expansion of CSP progenitors, we hypothesize the flt3L contributes to the 
preservation of a multipotent progenitor phenotype during ex vivo expansion. This 
also appears to be the case in vivo considering the reduced CD31- progenitor cell 
signature seen in freshly isolated flt3L-/- SP-CPCs. In this context, we recently 
tracked the transcriptional expression levels of primitive markers of multipotency in 
expanded wt and flt3L-/- SP-CPCs. We observed an overall passage-dependent down-
regulation of some of these markers in both strains, suggesting a partial loss of 
multipotent properties during in vitro expansion. Interestingly, this down-regulation 
was more pronounced in flt3L-/- CPCs, suggesting an accelerated loss of progenitor 
characteristics that might affect their ability to commit and ultimately differentiate. 
We are currently working on corroborating this hypothesis by tracking stemness 
markers as well as cardiac lineage markers during CSP cell expansion and during the 
differentiation process into the different lineages in order to unveil differences 
between genotypes (i.e., wt versus flt3L-/-). 
Regarding the molecular mechanisms that might regulate the behaviour of flt3L-/- 
CPCs, we identified the cell cycle regulator p63 (160) as markedly down-regulated in 
expanded (but not freshly isolated) ftl3L-/- CSP cells. P63 is a suppressor of 
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tumorigenesis and it affects several cellular mechanisms such as stemness, senescence, 
cell death and cell cycle arrest, which are all involved in cancer development (161). 
Interestingly, the p63 isoform TAp63 plays an important role in the maintenance and 
renewal of epidermal precursors. Loss of TAp63 leads to hyper-proliferation and 
senescence, and causes premature aging of these cells (162). TAp63 is also important 
for heart development and early embryonic stem cell (ESC) cardiogenesis. P63-
deficient mice die soon after birth, but they show dilated cardiomyopathy at the 
embryonic stage. Compared to wt ESCs, ESCs deficient for p63 were unable to 
produce beating CMCs, likely due to a down-regulation of cardiac transcription 
factors and sarcomeric proteins (163). Using murine embryonic fibroblasts, Ma et al. 
identified the Stat3/p63/Notch cascade downstream of Akt as an important regulator 
of the balance between cell proliferation and differentiation (164). 
We observed depletion of quiescent CPCs in systemically flt3L-deficient mice. We 
could reproduce a similar phenotype in mice treated with the flt3-inhibitor quizartinib 
for 28 consecutive days, suggesting that CSP homeostasis might be sensitive to  the 
temporally restricted inhibition of flt3 in the adult heart, which would also raise the 
possibility of potential cardiac side effects of targeted, but short-lasting treatments as 
used for cancer therapy. In this context we want to treat wt and flt3L-/- mice with 
recombinant flt3L in order to rescue (at least partially) the CSP depletion and to 
verify that this phenotype directly depends on the availability of flt3L in the 
surroundings of the CPC niche. 
 
We are also interested in a probable link between the rarefaction of the 
microvasculature and the CPC dysfunction, as suggested by the first results of the 
tube formation assay, showing an incapacity of flt3L-deficient progenitor cells to 
differentiate into endothelial cells capable to organize in tube-like structure.  
We are also currently investigating the mechanisms, which are responsible for the 
apparently protective role of flt3L ablation in the early phase of post-MI cardiac 
remodelling. Interestingly, our most recent findings show a transcriptional pattern 
(Table 7) in favour of a stronger and possibly more efficient inflammatory response to 
MI in the flt3L-/- hearts. We are going to test the hypothesis that flt3L ablation is 
responsible for an immuno-modulation that enhances the early inflammatory response 
and facilitates leucocyte migration after injury. 
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Taken together, the presented results as well as the results from our still ongoing 
studies will advance our understanding of CPC biology and of heart-intrinsic as well 
as of systemic roles of cancer drug targets and how their inhibition is affecting the 
heart. 
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Other contributions 
Cell therapy is a modern and still developing opportunity to treat cardiovascular 
disease. To promote myocardial regeneration, clinical trials have initially focused on 
the use of bone marrow-derived cells and have obtained very mixed results. Recent 
studies have switched the focus on cardiac-committed and/or cardiac resident 
progenitor cells. In the review article “Regenerative therapy for cardiovascular 
disease” we summarize current knowledge on different extracardiac as well as cardiac 
cell sources and highlight recent advances and backlashes in the field of cardiac cell 
therapy (74).  
Over the past few years we deepened our studies on the regulation and role of the 
CSP, a specific progenitor cell population residing in the adult heart, and worked on 
adaptations and the fine-tuning of culture and differentiation techniques of these cells. 
Part of this work is reported in the chapter “Cell therapy for cardiac regeneration” 
enclosed in “Translating Regenerative Medicine to Clinics” (insert the following 
reference: Kuster GM, Della Verde G, Liao R, Pfister O. Cell Therapy for Cardiac 
Regeneration. In: J. Laurence, M. Van Beusekom, P. Baptista, A. Atala, eds. 
Translating Regenerative Medicine to Clinics. United States of America: Academic 
Press, Elsevier Inc., 2016; pp. 266-283.) and in the recently published work “Polo-like 
kinase 2 is dynamically regulated to coordinate proliferation and early lineage 
specification downstream of YAP in cardiac progenitor cells” (Mochizuki et al., J Am 
Heart Assoc. 2017). In addition, a manuscript detailing adaptations in culture and 
differentiation techniques of CPCs is currently in preparation (invited submission to 
JoVE).  
I was also involved in the overall management and the conduction of experiments 
within the scope of other studies ongoing in the laboratory, in particular in vivo work 
addressing the role of NOX1 in metabolic heart disease (manuscript submitted).  
The work published or in preparation as well as congress contributions are listed 
below. 
REVIEW ARTICLE
Regenerative therapy for cardiovascular disease
OTMAR PFISTER, GIACOMO DELLA VERDE, RONGLIH LIAO, and GABRIELA M. KUSTER
BASEL, SWITZERLAND; AND BOSTON, MASS
Recent insights into myocardial biology uncovered a hereto unknown regenerative
capacity of the adult heart. The discovery of dividing cardiomyocytes and the iden-
tification and characterization of cardiac stem and progenitor cells with myogenic
and angiogenic potential have generated new hopes that cardiac regeneration
and repair might become a therapeutic option. During the past decade, multiple
candidate cells have been proposed for cardiac regeneration, and their mecha-
nisms of action in the myocardium have been explored. Initial clinical trials have
focused on the use of bone marrow-derived cells to promote myocardial regenera-
tion in ischemic heart disease and have yielded very mixed results, with no clear
signs of clinically meaningful functional improvement. Although the efficiency of
bona fide cardiomyocyte generation is generally low, stem cells delivered into the
myocardium act mainly via paracrine mechanisms. More recent studies taking
advantage of cardiac committed cells (eg, resident cardiac progenitor cells or
primed cardiogenic mesenchymal stem cells) showed promising results in first clin-
ical pilot trials. Also, transplantation of cardiomyogenic cells generated by induced
pluripotent stemcells and genetic reprogramming of dividing nonmyocytes into car-
diomyocytes may constitute attractive new regenerative approaches in cardiovas-
cular medicine in the future. We discuss advantages and limitations of specific cell
types proposed for cell-based therapy in cardiology and give an overview of the first
clinical trials using this novel therapeutic approach in patients with cardiovascular
disease. (Translational Research 2014;-:1–14)
Abbreviations: BMC¼ bonemarrow-derived cell; BMSC¼ bonemarrow stem cell; CADUCEUS¼
Cardiosphere-Derived Autologous StemCells to Reverse Ventricular Dysfunction; CD¼Cluster of
differentiation; SCF¼ stemcell factor; c-kit¼ receptor for SCF;CSC¼cardiac stemcell; ESC¼em-
bryonic stem cells; HF ¼ heart failure; iPS ¼ induced pluripotent stem cell; MSC ¼ mesenchymal
stem cell; SCIPIO¼ StemCell Infusion in Patients With Ischemic Cardiomyopathy; SP¼ side popu-
lation
D espite significant advances in the treatment ofacute myocardial infarction, stroke, and hyper-tension, cardiovascular disease continues to re-
main the leading cause of death in developed countries.1
As the common final sequel of virtually all cardiac dis-
eases, heart failure (HF) is themajor contributor to cardio-
vascular morbidity and mortality. In the Western world,
an estimated 1%–2% of the population experience HF,
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Chapter 18
Cell Therapy for Cardiac Regeneration
Gabriela M. Kuster, Giacomo Della Verde, Ronglih Liao, Otmar Pfister
Key Concepts
1.  The heart is capable of very limited cell replacement through cardiomyocyte division and differentiation of heart-resident progenitor
cells, but these endogenous regenerative resources are insufficient to compensate for major cell loss, which is at the core of heart
failure. Novel therapeutic approaches including cell transplantation and cellular reprogramming aiming at the regeneration of lost
cardiac tissue are currently in preclinical and early clinical testing.
2.  A variety of extracardiac and heart-resident stem and progenitor cells have been characterized, all of them having their inherent
strengths and limitations. These cells are transplanted through either intramyocardial or intracoronary application.
3.  Bone marrow-derived cells act mainly through paracrine mechanisms. Despite promising preclinical and early clinical results,
more rigorously designed clinical trials employing surrogate endpoints failed to prove clear efficacy, and a larger phase 3 mortality
trial is currently ongoing.
4.  Heart-resident cardiac stem and progenitor cells have cardiomyogenic differentiation potential, and preclinical and first small
clinical trials yielded encouraging results. However, their availability is limited and amplification time-consuming, preventing
their use in acute cardiac injury (acute myocardial infarction). A first study testing allogeneic cardiosphere-derived cells in
humans is currently ongoing.
5.  Embryonic stem cells (ESCs) and inducible pluripotent stem cells (iPS) have high plasticity, however, the suitability of cardiogenic
cells derived from ESCs and iPS may be limited by yet unsolved safety issues including immunogenicity, tumorigenicity, and
genetic instability.
List of Abbreviations
BCRP Breast cancer resistance protein
BMC Bone marrow-derived cell
BMMNC Bone marrow mononuclear cell
BMSC Bone marrow stem cells
CCTRN Cardiovascular cell therapy research network
CD Cluster of differentiation
c-kit Receptor for SCF
CSC Cardiac stem cell
CXCR4 Chemokine receptor 4
DNA Deoxyribonucleic acid
EPC Endothelial progenitor cell
ESC Embryonic stem cell
G-CSF Granulocyte-colony stimulating factor
HSC Hematopoietic stem cell
iPS Induced pluripotent stem cell
Isl-1 Islet 1
KLF4 Kruppel like factor 4
MDR Multidrug resistance protein
MSC Mesenchymal stem cell
Oct-4 Octamer binding transcription factor 4
RNA Ribonucleic acid
Sca-1 Stem cell antigen 1
SCF Stem cell factor
Polo-Like Kinase 2 is Dynamically Regulated to Coordinate
Proliferation and Early Lineage Specification Downstream of
Yes-Associated Protein 1 in Cardiac Progenitor Cells
Michika Mochizuki, PhD; Vera Lorenz, MSc; Robert Ivanek, PhD; Giacomo Della Verde, MSc; Emanuele Gaudiello, PhD; Anna Marsano, PhD;
Otmar Pfister, MD; Gabriela M. Kuster, MD
Background-—Recent studies suggest that adult cardiac progenitor cells (CPCs) can produce new cardiac cells. Such cell formation
requires an intricate coordination of progenitor cell proliferation and commitment, but the molecular cues responsible for this
regulation in CPCs are ill defined.
Methods and Results-—Extracellular matrix components are important instructors of cell fate. Using laminin and fibronectin, we
induced two slightly distinct CPC phenotypes differing in proliferation rate and commitment status and analyzed the early
transcriptomic response to CPC adhesion (<2 hours). Ninety-four genes were differentially regulated on laminin versus fibronectin,
consisting of mostly downregulated genes that were enriched for Yes-associated protein (YAP) conserved signature and TEA domain
family member 1 (TEAD1)-related genes. This early gene regulation was preceded by the rapid cytosolic sequestration and
degradation of YAP on laminin. Among the most strongly regulated genes was polo-like kinase 2 (Plk2). Plk2 expression depended on
YAP stability and was enhanced in CPCs transfected with a nuclear-targeted mutant YAP. Phenotypically, the early downregulation of
Plk2 on laminin was succeeded by lower cell proliferation, enhanced lineage gene expression (24 hours), and facilitated
differentiation (3 weeks) compared with fibronectin. Finally, overexpression of Plk2 enhanced CPC proliferation and knockdown of
Plk2 induced the expression of lineage genes.
Conclusions-—Plk2 acts as coordinator of cell proliferation and early lineage commitment in CPCs. The rapid downregulation of
Plk2 on YAP inactivation marks a switch towards enhanced commitment and facilitated differentiation. These findings link early
gene regulation to cell fate and provide novel insights into how CPC proliferation and differentiation are orchestrated. ( J Am Heart
Assoc. 2017;6:e005920. DOI: 10.1161/JAHA.117.005920.)
Key Words: cardiac progenitor cells • cell fate • extracellular matrix • polo-like kinase 2 • Yes-associated protein
T he adult mammalian heart has a limited capacity of cellreplacement, which in case of injury, such as myocardial
infarction, is insufficient to restore cardiac cellularity and
function. The resulting heart failure is a major cause of
morbidity and mortality, and an intense search for therapeutic
strategies to promote cardiac regeneration is currently
ongoing. Such an approach, however, requires a clear
understanding of the molecular mechanisms orchestrating
cardiac cell replacement. It is now well established that the
adult heart harbors cardiac progenitor cells (CPCs), which are
—in principal—capable of self-renewal1,2 and differentiation
into cardiac lineages, including cardiomyocytes, endothelial
cells, and vascular smooth muscle cells. A variety of markers
and techniques for their identification and isolation have been
reported.3 In preclinical studies, various populations, including
c-kit+ CPCs, cardiosphere-derived cells, and cardiac side
population (SP) CPCs, either endogenously or on in vitro
expansion and transplantation, contribute to cardiac cell
renewal after injury.4–7 Clinical trials using c-kit+ CPCs and
cardiosphere-derived cells to induce regeneration of the
postinfarct myocardium in humans have been initiated.8,9
Freshly isolated CPCs are low in numbers and require
amplification before being transplanted into the injured heart
for therapeutic application. Isolated CPCs can be readily
expanded in vitro while keeping their multilineage
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